fluorouracil has been researched along with Bone Neoplasms in 323 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 9.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 9.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The purpose of this prospective, nonrandomized, controlled study was to compare the regimen of continuously administering trastuzumab and capecitabine (HX) with the regimen of lapatinib plus capecitabine (LX) for metastatic breast cancer (MBC) patients who are resistant to trastuzumab and have previously received taxane treatment." | 9.17 | Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. ( Bian, L; Jiang, Z; Wang, T; Zhang, S, 2013) |
| "External beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin." | 9.17 | Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. ( Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 9.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer." | 9.14 | Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. ( Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM, 2010) |
| "To determine the response rate and toxicity profile of trastuzumab and capecitabine in women with HER2-overexpressing advanced breast cancer." | 9.13 | A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. ( Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 9.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 9.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 9.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 9.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer." | 9.11 | Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 9.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "To assess the activity of paclitaxel in combination with 5-fluorouracil (5-FU) and leucovorin in breast cancer, a phase II trial was conducted in women with metastatic disease." | 9.09 | Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ( Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y, 2000) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 9.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "The clinical efficacy of "CMF" chemotherapy, (cyclophosphamide, methotrexate, 5-fluorouracil), was evaluated on advanced and recurrent breast cancer." | 9.07 | [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan]. ( Adachi, I; Fukami, A; Koyama, H; Nomura, Y; Tominaga, T, 1994) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 9.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "In this study, 30 patients with metastatic breast cancer were treated with 5-Fluorouracil (5-FU) and high-dose Folinic acid, using a new sequential dosing schedule." | 9.07 | Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. ( Bellora, G; Bergamino, T; Ciancio, A; Ferrero, A; Katsaros, D; Sismondi, P; Zola, P, 1992) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 9.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "The Southeastern Cancer Study Group, in a prospectively randomized study involving patients with advanced breast cancer, has compared a low dose intermittently administered five-drug regimen including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) with an aggressively administered three-drug regimen including cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF)." | 9.05 | A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. ( Bartolucci, A; Carpenter, J; Krauss, S; Lefante, J; Smalley, RV; Vogel, C, 1983) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 9.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 7.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 7.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 7.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 7.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer." | 7.76 | [An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 7.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "We report a case of metastatic breast cancer with leptomeninges and multiple bone metastases that showed an excellent response to the combination of trastuzumab and capecitabine; therapeutic effect was evaluated by MRI at follow-up." | 7.75 | Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. ( Aogi, K; Fujiuchi, N; Matsuura, K; Misumi, M; Okubo, K; Osaki, A; Saeki, T; Sano, H; Shigekawa, T; Takeuchi, H, 2009) |
| "Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease." | 7.74 | [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. ( Fujii, H; Inoue, A; Inoue, M; Inoue, S; Kunitomo, K; Takahashi, H, 2008) |
| "A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation." | 7.73 | Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 7.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer." | 7.73 | [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. ( Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K, 2006) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 7.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)." | 7.70 | Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care. ( Higashi, Y; Iino, Y; Ishiguro, S; Kurihara, T; Morishita, Y; Suemasu, K; Tabei, T; Takeda, F, 1998) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 7.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)." | 7.69 | [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 7.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 7.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer." | 7.67 | [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer]. ( Dabag, S; Rieche, K; Scharlau, L, 1986) |
| "One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily." | 7.67 | Megestrol acetate therapy for advanced breast cancer. ( Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW, 1985) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 7.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer." | 7.66 | [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1982) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 6.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| "Celecoxib was never discontinued for toxicity." | 6.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 6.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 6.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 6.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| "Thymoquinone (TMQ) is a pharmacological component of black cumin that has multiple anti-tumorigenic effects." | 5.43 | Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells. ( Bayram, R; Benek, SB; Sarman, H, 2016) |
| "Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome." | 5.42 | [A case of lacrimal duct obstruction caused by capecitabine]. ( Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2015) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | 5.36 | Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "A 51-year-old patient had recurrent breast cancer with liver metastases." | 5.36 | [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective]. ( Hata, K; Hirai, I; Maebeya, S; Miki, Y; Oota, F; Tanaka, T; Tanino, H, 2010) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 5.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 5.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| " This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer." | 5.30 | Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 5.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 5.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| "To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil." | 5.20 | Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil. ( Bu, JG; Chen, BY; Chen, KQ; Cheng, JL; Feng, J; Gao, WW; Liang, WC; Liang, Y; Xu, YC, 2015) |
| "The purpose of this prospective, nonrandomized, controlled study was to compare the regimen of continuously administering trastuzumab and capecitabine (HX) with the regimen of lapatinib plus capecitabine (LX) for metastatic breast cancer (MBC) patients who are resistant to trastuzumab and have previously received taxane treatment." | 5.17 | Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer. ( Bian, L; Jiang, Z; Wang, T; Zhang, S, 2013) |
| "External beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin." | 5.17 | Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin. ( Brenner, B; Fenig, E; Kaufman, B; Kundel, Y; Nasser, NJ; Pfeffer, RM; Purim, O; Rizel, S; Stemmer, SM; Sulkes, A; Symon, Z; Yerushalmi, R, 2013) |
| "To evaluate the efficacy and safety of docetaxel plus thiotepa(TXT/TSPA) and docetaxel plus capecitabine(TXT/CAPE) in patients with metastatic breast cancer." | 5.15 | [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. ( Che, L; DI, Lj; Jia, J; Jiang, Hf; Liang, X; Ren, J; Song, Gh; Wang, Xl; Yang, Hb; Yu, J; Zhang, J; Zhou, Xn; Zhu, Yl, 2011) |
| "PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer." | 5.14 | Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. ( Barton, C; Button, P; de Fátima Dias Gaui, M; Hersberger, V; Jassem, J; Morales-Vasquez, F; Pivot, X; Reyes, DO; Torres, AA; Wardley, AM; Zetina, LM, 2010) |
| "To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer." | 5.13 | Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008) |
| "To determine the response rate and toxicity profile of trastuzumab and capecitabine in women with HER2-overexpressing advanced breast cancer." | 5.13 | A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. ( Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 5.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "A pilot phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent regimen of capecitabine (Xeloda) in patients with advanced or recurrent breast cancer." | 5.12 | A pilot phase II study of capecitabine in advanced or recurrent breast cancer. ( Kimura, T; Saeki, T; Taguchi, T; Toi, M, 2006) |
| "The combination of docetaxel and capecitabine provides a well-tolerated and active chemotherapy regimen for metastatic breast cancer." | 5.12 | [Efficacy of docetaxel combined capecitabine on metastatic breast cancer]. ( Jiang, WQ; Shi, YX; Wang, XX; Yuan, ZY; Zhang, DS; Zhou, ZM, 2007) |
| "We evaluated previously established regimens of capecitabine plus vinorelbine in older patients with advanced breast cancer stratified for presence versus absence of bone metastases." | 5.12 | Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). ( Ballabeni, P; Hess, D; Koberle, D; Mattmann, S; Pagani, O; Rauch, D; Ribi, K; Rochlitz, C; Schonenberger, A; Schuller, JC; Thurlimann, B, 2007) |
| "Strontium-89 is an established alternative for the alleviation of bone pain in prostate cancer." | 5.11 | Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. ( Edgren, M; Ginman, C; Kälkner, KM; Nilsson, S; Nordström, B; Ryberg, M; Strang, P; Westlin, JE; Zimmermann, R, 2005) |
| "A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the combination of fluorouracil 500 mg/m(2), epirubicin 50 mg/m(2) and cyclophosphamide 500 mg/m(2) (FEC) every 3 weeks." | 5.10 | Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. ( Andreesen, R; Bodenstein, H; Clemens, M; Fehnle, K; Fischer, JT; Heidemann, E; Hirschmann, WD; Kaufmann, M; König, M; Mahlke, M; Oberhoff, C; Scharl, A; Schulze, M; Souchon, R; Stoeger, H, 2002) |
| "To assess the activity of paclitaxel in combination with 5-fluorouracil (5-FU) and leucovorin in breast cancer, a phase II trial was conducted in women with metastatic disease." | 5.09 | Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer. ( Cohen, A; Hande, KR; Johnson, DH; Meshad, M; Nicholson, BP; Paul, DM; Shyr, Y, 2000) |
| "The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients." | 5.08 | Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? ( Blomqvist, C; Franssila, K; Hietanen, P; Niskanen, E; Nordling, S; Wasenius, VM, 1995) |
| "One hundred ninety-five women (141 eligible) whose disease was in CR or in CR except for bone metastases following six cycles (6 months) of doxorubicin-containing induction treatment were randomized to receive cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, and halotestin [CMF(P)TH] or observation." | 5.08 | Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. ( Abeloff, MD; Cummings, FJ; Falkson, G; Gelman, RS; Osborne, CK; Pandya, KJ; Sledge, GW; Tormey, D, 1998) |
| " We conducted a Phase II trial of an anthracycline analogue, pirarubicin, administered in combination with 5-fluorouracil and cyclophosphamide every 3 weeks, as front-line chemotherapy in women with metastatic breast cancer." | 5.08 | Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. ( Buzdar, A; Dhingra, K; Fraschini, G; Frye, D; Hortobagyi, GN; Newman, RA; Smith, T; Theriault, R; Walters, R, 1995) |
| "The clinical efficacy of "CMF" chemotherapy, (cyclophosphamide, methotrexate, 5-fluorouracil), was evaluated on advanced and recurrent breast cancer." | 5.07 | [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan]. ( Adachi, I; Fukami, A; Koyama, H; Nomura, Y; Tominaga, T, 1994) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 5.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "In this study, 30 patients with metastatic breast cancer were treated with 5-Fluorouracil (5-FU) and high-dose Folinic acid, using a new sequential dosing schedule." | 5.07 | Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients. ( Bellora, G; Bergamino, T; Ciancio, A; Ferrero, A; Katsaros, D; Sismondi, P; Zola, P, 1992) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 5.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "Thirty-seven patients with poor prognosis, metastatic breast cancer were treated with 5-fluorouracil, vinblastine, and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (FUVA) induction chemotherapy." | 5.06 | Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study. ( Ellis, GK; Goldberg, RS; Green, S; Livingston, RB; Schulman, S; Tranum, BL, 1989) |
| "A total of 97 women with good-risk metastatic breast cancer received therapy with cyclophosphamide, doxorubicin, and 5-FU; half of these patients were randomly allocated to receive levamisole, 2." | 5.06 | Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial. ( Carpenter, JT; Raney, M; Smalley, RV; Vogel, CL; Weiner, RS, 1986) |
| "The Southeastern Cancer Study Group, in a prospectively randomized study involving patients with advanced breast cancer, has compared a low dose intermittently administered five-drug regimen including cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) with an aggressively administered three-drug regimen including cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF)." | 5.05 | A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer. ( Bartolucci, A; Carpenter, J; Krauss, S; Lefante, J; Smalley, RV; Vogel, C, 1983) |
| "Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed." | 5.05 | The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Carbone, PP; Cummings, FJ; Falkson, G; Falkson, HC; Gelman, RS; Tormey, DC, 1985) |
| "A prospective study with two cytotoxic combinations (cyclophosphamide, methotrexate, and fluorouracil (CMF), and adriamycin plus vincristine (AV)) was carried out in 110 patients with advanced breast cancer." | 5.04 | Response and survival in advanced breast cancer after two non-cross-resistant combinations. ( Bonadonna, G; Brambilla, C; De Lena, M; Rossi, A; Valagussa, P, 1976) |
| " For those epothilones that have gone on to clinical development (epothilone B, ixabepilone, BMS-310705, ZK-EPO, KOS-862, and KOS-1584), preclinical investigations in breast cancer models are reviewed." | 4.84 | Preclinical investigations with epothilones in breast cancer models. ( Burris, HA, 2008) |
| "Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC." | 3.85 | Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017) |
| "The purpose of this study was to analyze outcomes for the treatment of locally advanced temporal bone cancer by means of concomitant chemoradiotherapy (CCRT) with a combination of cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (TPF)." | 3.83 | Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone. ( Ejima, Y; Hasegawa, S; Hashikawa, K; Kenji, Y; Kiyota, N; Kohmura, E; Nibu, K; Nomura, T; Otsuki, N; Sakakibara, S; Sasaki, R; Shinomiya, H; Yamashita, D, 2016) |
| " Here, we report an advanced case of breast cancer with vertebra-Th7 metastasis that showed complete response to combined treatments with formalin-fixed autologous tumor vaccine (AFTV), palliative radiation therapy with 36 Gy, and adjuvant chemotherapy with standardized CEF (cyclophosphamide, epirubicin, and 5FU), zoledronic acid, and aromatase inhibitors following mastectomy for the breast tumor." | 3.79 | Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report. ( Kuranishi, F; Ohno, T, 2013) |
| "We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 3.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
| " They had osteosarcoma in methotrexate group (n=7), gastrointestinal malignancies in 5FU group (n=9) and breast cancer in the capecitabine group (n=2)." | 3.78 | Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients. ( Akbulut, H; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Karabulut, HG; Tukun, A; Utkan, G; Yalcin, B, 2012) |
| "There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)." | 3.77 | Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011) |
| "Capecitabine is effective and well tolerated in patients with anthracycline- and/or taxane-pre-treated metastatic breast cancer." | 3.76 | Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer. ( Amari, M; Ishida, T; Ohuchi, N; Takeda, M, 2010) |
| "Capecitabine + docetaxel combination therapy proves highly effective against the advanced or recurrent breast cancer." | 3.76 | [An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6]. ( Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Shimizu, T; Tanaka, M; Tani, T; Umeda, T, 2010) |
| "The purpose of the present study is to evaluate what clinical factors affect the efficacy, time to treatment failure (TTF), and overall survival (OS) of oral capecitabine monotherapy in heavily pretreated patients with metastatic breast cancer (MBC)." | 3.75 | Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer. ( Hatake, K; Ito, Y; Iwase, T; Matsuura, M; Osako, T; Sugihara, T; Takahashi, S; Tokudome, N; Ushijima, M, 2009) |
| "We report a case of metastatic breast cancer with leptomeninges and multiple bone metastases that showed an excellent response to the combination of trastuzumab and capecitabine; therapeutic effect was evaluated by MRI at follow-up." | 3.75 | Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report. ( Aogi, K; Fujiuchi, N; Matsuura, K; Misumi, M; Okubo, K; Osaki, A; Saeki, T; Sano, H; Shigekawa, T; Takeuchi, H, 2009) |
| "We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy." | 3.74 | Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007) |
| "We reported a case of DIC who was administered FEC90 (5-FU 1,000 mg/body, epirubicin 170 mg/body, cyclophosphamide 1,000 mg/body) for advanced breast cancer." | 3.74 | [A case of advanced breast cancer leading to DIC after chemotherapy]. ( Doi, Y; Endo, Y; Ishizuka, S; Kai, K; Matsumoto, Y; Morikawa, T; Nabeyama, A; Nagahiro, I; Nakashima, A; Nobuhisa, T; Sato, S; Watanabe, T; Yamada, T; Yoshida, K, 2007) |
| "Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease." | 3.74 | [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. ( Fujii, H; Inoue, A; Inoue, M; Inoue, S; Kunitomo, K; Takahashi, H, 2008) |
| "A 41-year-old woman who was undergoing oral chemotherapy with capecitabine for metastatic breast cancer presented with recurrent episodes of chest pain associated with electrocardiographic signs of diffuse ST segment elevation." | 3.73 | Acute coronary syndrome induced by oral capecitabine. ( Cardinale, D; Colombo, A; Colombo, N, 2006) |
| "We investigated 29 patients with advanced and recurrent breast cancers who underwent capecitabine therapy in the department." | 3.73 | [Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression]. ( Hironou, M; Ikeda, M; Kurebayashi, J; Nakashima, K; Nomura, T; Ookubo, S; Seki, M; Shiiki, S; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, Y, 2006) |
| "We conducted a concomitant administration of capecitabine (2,400 mg/day for 21 days followed by a 7-day interval) and trastuzumab (2 mg/kg weekly) to a 73-year-old female patient with impaired lower limb function diagnosed with bilateral breast cancer." | 3.73 | [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy]. ( Hiraoka, K; Imabun, S; Nakahara, M; Nakao, K; Tsujimoto, M; Yamagami, Y; Yoshidome, K, 2006) |
| " The pharmacokinetics of capecitabine--an active oral 5-fluorouracil prodrug for the treatment of advanced breast cancer--are not affected in patients with mild to moderate hepatic dysfunction, but there are no data available for patients with severe hyperbilirubinemia." | 3.72 | Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function. ( Kornek, GV; Scheithauer, W; Schüll, B, 2003) |
| "We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases." | 3.72 | [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. ( Fujio, N; Fukuda, Y; Koyama, I; Mayumi, K; Osugi, H; Takatori, H; Terakura, M; Tsukazaki, T; Tsukazaki, Y, 2004) |
| " We report the 1st case of capecitabine-induced toxic encephalopathy with epilepsy-like symptoms and diffuse white matter alterations on magnetic resonance imaging." | 3.72 | Toxic encephalopathy induced by capecitabine. ( Herrmann, R; Niemann, B; Pless, M; Rochlitz, C, 2004) |
| "A 33-year-old woman with T(4c)N(3) breast cancer with metastases in the skeleton (M(1)) received five cycles of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC regimen) before conception and during the first trimester." | 3.72 | Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. ( Andreadis, C; Charalampidou, M; Chouchos, N; Diamantopoulos, N; Mouratidou, D, 2004) |
| "We herein report the case of a patient with recurrent breast cancer who showed a remarkable improvement in her quality of life (QOL) as a result of a good response to medroxyprogesterone acetate (MPA)." | 3.70 | Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care. ( Higashi, Y; Iino, Y; Ishiguro, S; Kurihara, T; Morishita, Y; Suemasu, K; Tabei, T; Takeda, F, 1998) |
| "To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer." | 3.70 | [A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998) |
| "We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)." | 3.69 | [A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994) |
| "Sequential therapy consisting of methotrexate (MTX) and 5-FU was performed together with the administration of heparin and FOY in 10 cases of gastric cancer with disseminated intravascular coagulation (DIC) causing systemic bone metastasis." | 3.68 | [Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation]. ( Ibuka, T; Imai, K; Ishiwata, J; Kobayashi, T; Monma, K; Ohno, T; Onozawa, Y; Sakaki, N; Sasaki, T; Tabata, I, 1992) |
| "Forty-one women with advanced breast cancer were treated with cyclophosphamide, methotrexate, 5-FU, and prednisone." | 3.67 | Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer. ( Cadman, EC; Cross, J; Glick, JH; Horton, J; Taylor, SG, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 3.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "A clinical phase II study was performed to evaluate the therapeutic efficacy of simultaneously administered aminoglutethimide and polychemotherapy in 31 patients with predominant bone metastases of breast cancer." | 3.67 | [Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer]. ( Dabag, S; Rieche, K; Scharlau, L, 1986) |
| "One hundred twenty-four patients with metastatic breast cancer were treated with 40 mg of megestrol acetate four times daily." | 3.67 | Megestrol acetate therapy for advanced breast cancer. ( Cohen, SC; Gregory, EJ; Mims, CH; Oines, DW, 1985) |
| "Among fifty patients with bone metastases from breast cancer who were hospitalized between 1971 and 1980, 19 were given intermittent chemotherapy including both hormone-therapy (drostanolon propionate and tamoxifen) and a combination of cyclophosphamide, methotrexate, 5 FU, doxorubicin and vincristine (CMFDV)." | 3.66 | [Bone metastasis of breast cancer. Apropos of a series of 50 cases]. ( Alcalay, M; Bontoux, D; Daban, A; Vincent, D; Vincent-Joyeux, F, 1982) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 3.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "Twenty-four patients with confirmed Stage D carcinoma of the prostate were treated with a combination of bilateral orchiectomy, estrogens (diethylstilbestrol) and chemotherapy (5-fluorouracil), and cyclophosphamide soon after diagnosis was established." | 3.66 | Early combined hormonal and chemotherapy for metastatic prostatic carcinoma. ( Lurie, H; Mukamel, E; Nissenkorn, I; Servadio, C, 1983) |
| "Twenty-one patients, presenting with metastases only to bone from a primary adenocarcinoma of the breast having previously undergone mastectomy, tolerated aggressive cytotoxic chemotherapy (CAF--cyclophosphamide 500 mg/m2, Adriamycin 50 mg/m2, 5-fluorouracil 500 mg/m2 q 3 weeks) without significant clinical morbidity." | 3.66 | Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases. ( Malmud, LS; Scogna, DM; Smalley, RV, 1982) |
| "Combination chemotherapy with cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5-FU) (CAF therapy) was performed in 85 patients with advanced and recurrent breast cancer." | 3.66 | [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer]. ( Abe, O; Enomoto, K; Izuo, M; Koyama, H; Kubo, K; Nomura, Y; Sakai, K; Terasawa, T; Tominaga, T, 1982) |
| "Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy." | 3.66 | Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. ( Ikard, M; Shippel, RM; Soloway, MS, 1979) |
| "Forty patients with metastatic breast cancer who had received no previous cytotoxic therapy were treated with a combination chemotherapy program CMF (P), which included methotrexate, 60 mg/m2, and 5-fluorouracil, 700 mg/m2 intravenously on the first and eighth days, in addition to cyclophosphamide, 100 mg/m2, and prednisone, 40 mg/m2, by mouth daily from the first to the fourteenth day of a 28-day cycle." | 3.65 | Combination chemotherapy for advanced breast cancer: response and effect on survival. ( Canellos, GP; Chabner, BA; DeVita, VT; Gold, GL; Schein, PS; Young, RC, 1976) |
| "Twenty-five patients with advanced metastatic breast cancer were treated with the combination of methotrexate 60 mg/M(2) and 5-fluorouracil 700 mg/M(2) intravenously on the first and eighth days, and cyclophosphamide 100 mg/M(2) and prednisone 40 mg/M(2) by mouth daily for the first 14 days of a 28-day cycle." | 3.65 | Cyclical combination chemotherapy for advanced breast carcinoma. ( Canellos, GP; Chabner, BA; Devita, VT; Gold, GL; Schein, PS; Young, RC, 1974) |
| "Thirty patients with advanced pancreatic cancer who were pretreated with gemcitabine received oxaliplatin (85 mg/m(2)) on days 1 and 15 followed by leucovorin (20 mg/m(2)) and 5-fluorouracil (500 mg/m(2)) on days 1, 8, and 15." | 2.78 | Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. ( El-Hadaad, HA; Wahba, HA, 2013) |
| "The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome." | 2.76 | A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011) |
| "Grade 3 neutropenia was seen in seven patients and grade 4 in one patient." | 2.75 | Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma. ( Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T, 2010) |
| " Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation." | 2.74 | Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009) |
| " The primary end-point was to establish the maximum tolerable dose (MTD) of capecitabine when combined with (188)Re-HEDP." | 2.74 | (188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. ( Bosma, TB; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2009) |
| "Celecoxib was never discontinued for toxicity." | 2.73 | Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation. ( Carlini, P; Cognetti, F; Fabi, A; Ferretti, G; Gelibter, A; Melucci, E; Metro, G; Milella, M; Mottolese, M; Papaldo, P; Russillo, M; Sperduti, I; Tomao, S, 2008) |
| "Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients." | 2.73 | Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. ( Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R, 2007) |
| "Metastatic breast cancer confined to the bones may have a better prognosis, especially hormone receptor-positive disease." | 2.72 | A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone ( Affronti, ML; Broadwater, G; Coniglio, D; Edwards, J; Madan, B; Marks, L; McDonald, C; Niedzwiecki, D; Peters, WP; Ross, M; Vandemark, R; Vredenburgh, JJ, 2006) |
| "The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first-line treatment for patients with locally advanced/metastatic breast carcinoma." | 2.71 | Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma. ( Bighin, C; Colozza, MA; Contu, A; Del Mastro, L; Durando, A; Garrone, O; Genta, F; Lambiase, A; Stevani, I; Venturini, M, 2003) |
| " The aim was to investigate the therapeutic efficacy and tolerance of mitomycin C (MMC) in combination with gemcitabine (GEM) or capecitabine (CAPE) in previously untreated patients with advanced biliary tract cancer." | 2.71 | Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. ( Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B, 2004) |
| "Metastatic breast cancer remains an incurable disease and the median overall survival has not significantly improved over the past two decades." | 2.69 | Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. ( Comandini, D; Fusco, V; Merlini, L; Naso, C; Palumbo, R; Porcile, G; Pronzato, P; Repetto, L; Rosso, R; Simoni, C; Venturino, A, 2000) |
| "AcF is highly active in breast cancer with acceptable toxicities and can be used before alkylating agent-based high-dose therapy." | 2.68 | Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. ( Cameron, DA; Gabra, H; Lee, LE; Leonard, RC; Mackay, J, 1996) |
| " Frequent dosage modifications were required with the dose intensity of 5-FU and alpha interferon of 57% and 58%, respectively." | 2.67 | Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer. ( Dreicer, R; Forest, PK; Williams, RD, 1994) |
| "Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991." | 2.67 | [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]. ( Zhou, JC, 1993) |
| "Hormone-refractory metastatic prostate cancer remains a therapeutic challenge." | 2.67 | Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. ( Blumenstein, BA; Boileau, M; Crawford, ED; Fletcher, WS; Rivkin, SE; Wozniak, AJ, 1993) |
| "Thirty-nine patients with head and neck cancer were entered into Phase I-II study of simultaneous radiation therapy with continuous infusion fluorouracil at 800 mg/m2/day and escalating doses of hydroxyurea." | 2.67 | Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. ( Haraf, DJ; Panje, WR; Vokes, EE; Weichselbaum, RR, 1991) |
| "Twenty-five patients with metastatic breast cancer were studied." | 2.67 | 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. ( Affronti, ML; Bast, RC; Eggleston, S; Johnston, C; Jones, RB; Rosner, GL; Ross, M; Shpall, EJ; Tepperburg, M; Vandermark, R, 1991) |
| "48 patients with metastatic breast cancer and extensive bone involvement were treated with salm-calcitonin and polychemo-therapy or hormonal treatment." | 2.65 | [Calcitonin in bone-metastasizing breast carcinoma. Results of a pilot study]. ( Beaufort, F; Gölles, M, 1984) |
| "Twenty-six patients with metastatic breast carcinoma who had measurable sites of disease were evaluated." | 2.65 | Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma. ( Aroney, RS; Dalley, DN; Levi, JA, 1980) |
| "Although patients with metastatic prostatic cancer may benefit from chemotherapy, impressive clinical responses are uncommon." | 2.65 | Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial. ( Brodkin, R; Cooper, MR; Howard, V; Jackson, DV; Muss, HB; Resnick, MI; Richards, F; Spurr, CL; Stuart, JJ; White, DR, 1981) |
| "Capecitabine is a prodrug of 5-fluorouracil, more easily administered by mouth; its transformation in 5-fluorouracil is performed in the liver." | 2.47 | Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D, 2011) |
| "The treatment of metastatic breast cancer aims to relieve symptoms by controlling disease and prolonging survival with better QOL." | 2.43 | [Chemotherapy for metastatic breast cancer]. ( Ito, Y; Tokudome, N, 2006) |
| "A patient with recurrent breast cancer, who was diagnosed with eyelid metastasis as a part of systemic metastases and in whom systemic chemotherapy was markedly effective, is reported." | 2.39 | Eyelid metastasis from breast cancer showing marked response to chemotherapy. ( Abe, K; Adachi, I; Kaneko, A; Narabayashi, M; Tokue, Y; Tsuda, H; Watanabe, T; Yin, DF; Zhang, GJ, 1995) |
| "The potential impact on cancer mortality from these treatment results is obvious." | 2.36 | Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. ( DeVita, VT; Weiss, RB, 1979) |
| "Multiple myeloma is a plasma cell malignancy that thrives in the bone marrow (BM), with frequent progression to new local and distant bone sites." | 1.56 | Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites. ( Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C, 2020) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "Stage IV squamous cell carcinoma of the anus outcomes are poor, but first-line chemotherapy can enable good response rates." | 1.46 | Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience. ( Benezery, K; Cavaglione, G; Doyen, J; Evesque, L; Follana, P; François, E; Reure, J; Tuan Falk, A, 2017) |
| "CTCs in 2 (10%) of 20 breast carcinomas, more than 1 CTC was detected before adjuvant therapy, and both cases showed a decrease to 0 after chemotherapy." | 1.46 | Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation. ( Kinoshita, S; Shimada, T; Takeyama, H; Uchida, K, 2017) |
| "Thymoquinone (TMQ) is a pharmacological component of black cumin that has multiple anti-tumorigenic effects." | 1.43 | Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells. ( Bayram, R; Benek, SB; Sarman, H, 2016) |
| "Capecitabine was discontinued 287 days after initiation owing to exacerbation of the hand-foot syndrome." | 1.42 | [A case of lacrimal duct obstruction caused by capecitabine]. ( Kawara, H; Mitani, T; Noguchi, Y; Shimizu, Y; Tamura, Y; Tokuyama, Y; Uchiyama, K, 2015) |
| "Irinotecan has synergism with 5-fluorouracil and shows efficacy in advanced breast cancer." | 1.42 | Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane. ( Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS, 2015) |
| "A cell line-specific, dose-related cytotoxicity was observed for 5-FdU-ale in all cancer cell lines tested, which was significantly less toxic than 5-FdU alone when compared to the benign osteoblasts or stromal cells." | 1.42 | In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis. ( Busch, C; Noor, S; Schem, C; Schott, S; Tiwari, S; Tower, RJ; Vallet, S, 2015) |
| "This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection." | 1.42 | [Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report]. ( Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015) |
| "Osteosarcoma is the most common primary malignancy of bone." | 1.40 | Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells. ( Fu, WM; Hsieh, IS; Yang, RS, 2014) |
| "The majority of patients with gastric cancer in developing countries present with advanced disease." | 1.38 | Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. ( Guven, M; Inal, A; Işikdogan, A; Kaplan, MA; Kuçukoner, M; Nas, N; Urakci, Z; Yunce, M, 2012) |
| "Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases." | 1.38 | Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "Sixteen months after the diagnosis of rectal cancer, the patient died." | 1.38 | [A case of advanced rectal cancer with lung and bone metastasis that was successfully treated with mFOLFOX6+bevacizumab]. ( Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kobayashi, H; Masuda, T; Matsuyama, T; Okazaki, S; Sugihara, K; Uetake, H; Yamauchi, S, 2012) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | 1.37 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen." | 1.36 | Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010) |
| "A 51-year-old patient had recurrent breast cancer with liver metastases." | 1.36 | [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective]. ( Hata, K; Hirai, I; Maebeya, S; Miki, Y; Oota, F; Tanaka, T; Tanino, H, 2010) |
| " Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment." | 1.35 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009) |
| "Esophageal adenosquamous carcinoma is a rare esophageal disease and prone to be misdiagnosed as esophageal squamous cell carcinoma." | 1.35 | [Clinical analysis of 22 cases of esophageal adenosquamous carcinoma]. ( Fu, JH; Lin, P; Long, H; Ma, GW; Rong, TH; Su, XD; Zhang, DK; Zhang, LJ, 2009) |
| "Cholangiocarcinoma is a malignant neoplasm arising from the biliary epithelium." | 1.34 | Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. ( Hsieh, CB; Huang, TW; Wang, CH, 2007) |
| " In April 2004, she had a recurrence manifesting itself as bone metastasis, partly because of poor compliance with the hospital-visit and dosing schedules." | 1.34 | [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine]. ( Akahane, T; Chiba, T; Hashimoto, Y; Yano, H, 2007) |
| "Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes." | 1.34 | Male breast cancer with mandibular metastasis. A case report. ( Amaddeo, P; Barbaglio, A; Faldi, F; Fontana, S; Ghilardi, R; Pericotti, S, 2007) |
| "All cases of breast carcinoma diagnosed during the period from 1989 to 2001 were retrospectively reviewed." | 1.34 | [Diagnosis and prognosis study of breast carcinoma with micropapillary component]. ( Chen, L; Fan, Y; Fu, L; Guo, XJ; Lang, RG; Sun, YL, 2007) |
| "Patients with esophageal cancer often develop metastatic disease after esophageal resection and generally receive cisplatin-based chemotherapy or chemoradiotherapy." | 1.34 | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. ( Fujita, H; Mori, N; Nagano, T; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Tanaka, Y; Yamana, H, 2007) |
| " Furthermore, she was administered tegafur/uracil (400 mg/day) 5 days weekly for pharmacokinetic modulating chemotherapy (PMC)." | 1.33 | [A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Ishikawa, T; Kamimura, T; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Watanabe, K; Yoshida, T, 2005) |
| "A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt." | 1.33 | [A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005) |
| "Bone metastases were the most frequent (83%)." | 1.33 | [Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases]. ( Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Karray, H; Khanfir, A, 2006) |
| "The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease." | 1.33 | A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Martínez Banaclocha, N; Pons Sanz, V; Rodríguez Lescure, A, 2006) |
| "She was first diagnosed as intrahepatic cholangiocarcinoma with hepatic, paraaortic lymphnodal and bone metastasis." | 1.33 | [A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy]. ( Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y, 2006) |
| " Since clinical studies have demonstrated that bisphosphonates (BPs), specific inhibitors of osteoclastic bone resorption, are beneficial for breast cancer patients with bone metastases, we next examined the effects of UFT combined with the BP zoledronic acid (ZOL) on established bone metastases." | 1.32 | Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. ( Hata, K; Hiraga, T; Ikeda, F; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T, 2003) |
| " The purpose of the present studies was to demonstrate the potent anticancer activity of SU11248 alone or in combination with conventional cytotoxic agents against several distinct preclinical models of breast cancer." | 1.32 | Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. ( Abrams, TJ; Cherrington, JM; Colombo, T; Holway, VW; Lee, LB; Murray, LJ; Pesenti, E; Pryer, NK, 2003) |
| "In addition, 5FC treatment of bone sarcomas caused a significant reduction in cancer-induced bone destruction (P < 0." | 1.32 | Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. ( Clohisy, DR; Goblirsch, M; Lewis, V; Lynch, C; Mantyh, P; Orchard, P; Pan, W; Ramnaraine, M, 2003) |
| "5 patients with colorectal cancer with multiple liver metastases underwent resection of primary lesions." | 1.32 | [Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer]. ( Abe, N; Ishii, Y; Itou, T; Nakayama, K; Takahashi, M, 2003) |
| "Endoscope and CT scan revealed type 3 gastric cancer with paraaortic lymph nodal metastasis." | 1.32 | [A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU]. ( Fujita, K; Gotoh, M; Hirata, I; Hongo, H; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H, 2004) |
| " He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11." | 1.32 | [A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004) |
| "We report a case of far advanced breast cancer showing an excellent response to chemo-endocrine therapy." | 1.31 | [A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy]. ( Hayashi, K; Kasuga, Y; Kondo, R; Munakata, Y; Nishimura, H; Takasuna, K, 2000) |
| "A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy in a 54-year-old woman, is reported." | 1.30 | [A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy]. ( Fujino, H; Itoshima, T; Kasamatsu, T; Kodama, M; Morita, Y; Yamamoto, H; Yamamoto, T, 1997) |
| "This suggested that the therapy for a breast cancer patient with distant metastasis must be considered according to the region of recurrence." | 1.30 | [A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer]. ( Ayabe, H; Hara, S; Hashizume, S; Itoyanagi, N; Oka, T; Shinguu, H; Tagawa, Y; Tooyama, H; Tou, K; Tsuji, H; Yamamoto, S; Yamazumi, K, 1997) |
| "For previously treated advanced breast cancer, there is no standard second-line therapy." | 1.30 | Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1997) |
| "We reported a case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate (MTX) and 5-fluorouracil (5-FU) sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil." | 1.30 | [A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil]. ( Kamei, M; Kawabata, H; Matsuda, K; Nishioka, M; Sasahara, K; Uchida, Y, 1998) |
| "Patients with metastatic breast cancer (MBC) have variable clinical courses." | 1.30 | Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. ( Adachi, I; Ando, M; Katsumata, N; Narabayashi, M; Omuro, Y; Watanabe, T; Yamamoto, N, 1998) |
| "Nocturnal infusion of 5-fluorouracil (5-FU) combined with pamidronate was performed in a 62-year-old male gastric cancer patient with multiple bone metastasis." | 1.30 | [A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate]. ( Fukano, S; Furuya, Y; Kinugasa, T; Kohno, N; Maekawa, Y; Sekimoto, K; Toyokawa, A, 1998) |
| "Measuring a bone resorption marker, ICTP, allows clinicians to monitor patients' responses to CAF therapy and may prevent prolonged ineffective therapy or unnecessary changes in therapy as a result of the flare phenomenon." | 1.30 | Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. ( Koizumi, M; Matsumoto, S; Ogata, E; Takahashi, S; Yamashita, T, 1999) |
| "An 80-year-old woman with metastatic bone cancer from ascending colon showed a remarkable response to combination therapy of 5-FU and radiation." | 1.30 | [Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report]. ( Masuda, M; Nakamura, N; Nakanishi, K; Okamoto, E; Satoh, M; Takeuchi, T; Tanihata, H; Terada, M; Ueno, Y; Yoshikawa, H, 1999) |
| "An advanced gastric cancer patient with multiple retroperitoneal lymph node metastases and bone metastases was treated with sequential MTX and 5-FU." | 1.29 | [A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil]. ( Anai, H; Furuyama, M; Ikejiri, K; Maekawa, S; Muranaka, T; Saku, M; Takeo, S; Yakabe, S, 1994) |
| "The phase I trial in breast cancer conducted by Peters et al." | 1.29 | Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. ( Purdy, MH, 1995) |
| "A case of Sick Sinus Syndrome probably secondary to cardiac metastasis in a patient affected by metastatic breast cancer is described." | 1.27 | [Sick sinus syndrome probably caused by cardiac metastases]. ( Pupillo, M; Salvati, F, 1983) |
| "Included in this study were 43 breast cancer patients treated with adjuvant chemotherapy who presented metastasis only in bone." | 1.27 | Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. ( Blumenschein, GR; Buzdar, AU; DeMartini, AL, 1983) |
| "43 metastatic cancer patients received 190 portable infusors over 24 hours or more." | 1.27 | [Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial]. ( Benahmed, M; Carde, P; Laplanche, A; Renaux, J; Rouesse, J; Sancho-Garnier, H; Spielmann, M, 1985) |
| "The treatment schedule for disseminated breast carcinoma has been developed." | 1.27 | [4-component chemotherapy and radiation therapy of breast cancer]. ( Aplevich, NN; Gritsaĭ, AA; Kondrat'eva, AP; Lichinitser, MR; Vyshinskaia, GV, 1986) |
| "The problems of defining response in prostatic cancer are discussed and a protocol for the future is outlined." | 1.26 | The non-hormone chemotherapy of prostatic cancer. ( Jones, MA; Williams, G, 1980) |
| "Patients with breast cancer may show an increased requirement for thiamin particularly when treated with 5-fluorouracil, and a number of metabolic disturbances in which ascorbic acid may play a central role." | 1.26 | Nutrition and breast cancer. ( Dickerson, JW, 1979) |
| "Since 1963, regional intra-arterial infusion of anti-cancer agents combined with surgery has been used in the treatment of 56 patients with osteosarcomas." | 1.26 | The results of surgical treatment combined with intra-arterial infusion of anti-cancer agents in osteosarcoma. ( AKAHOSHI, Y; Chen, SH; Kikuike, A; Nishimoto, T; Takeuchi, S; Yamamuro, T; Yonezawa, H, 1976) |
| "In evaluating response by sites of metastases, lymph nodes (30%), lung nodules (22%), and subcutaneous deposits (2/3) had the highest incidence of C." | 1.25 | An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. ( Catalano, RB; Creech, RH; Engstrom, PF; Mastrangelo, MJ, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 86 (26.63) | 18.7374 |
| 1990's | 60 (18.58) | 18.2507 |
| 2000's | 102 (31.58) | 29.6817 |
| 2010's | 69 (21.36) | 24.3611 |
| 2020's | 6 (1.86) | 2.80 |
| Authors | Studies |
|---|---|
| Ouyang, L | 1 |
| He, D | 1 |
| Zhang, J | 2 |
| He, G | 1 |
| Jiang, B | 1 |
| Wang, Q | 1 |
| Chen, Z | 1 |
| Pan, J | 1 |
| Li, Y | 3 |
| Guo, L | 1 |
| Witkowska, M | 1 |
| Maciejewska, N | 1 |
| Ryczkowska, M | 1 |
| Olszewski, M | 1 |
| Bagiński, M | 1 |
| Makowiec, S | 1 |
| Dell'Aquila, E | 1 |
| Rossini, D | 1 |
| Fulgenzi, CAM | 1 |
| Passardi, A | 1 |
| Tamburini, E | 2 |
| Vetere, G | 1 |
| Carullo, M | 1 |
| Citarella, F | 1 |
| Antoniotti, C | 1 |
| Zaniboni, A | 1 |
| Pietrantonio, F | 1 |
| Spagnoletti, A | 1 |
| Marmorino, F | 1 |
| Borelli, B | 1 |
| Allegrini, G | 1 |
| Lonardi, S | 1 |
| Nappo, F | 1 |
| Masi, G | 2 |
| Cremolini, C | 1 |
| Santini, D | 1 |
| Xu, X | 1 |
| Zhang, C | 2 |
| Trotter, TN | 1 |
| Gowda, PS | 1 |
| Lu, Y | 1 |
| Ponnazhagan, S | 1 |
| Javed, A | 1 |
| Li, J | 1 |
| Yang, Y | 1 |
| Sastre, J | 1 |
| Orden, V | 1 |
| Martínez, A | 1 |
| Bando, I | 1 |
| Balbín, M | 1 |
| Bellosillo, B | 1 |
| Palanca, S | 1 |
| Peligros Gomez, MI | 1 |
| Mediero, B | 1 |
| Llovet, P | 1 |
| Moral, VM | 1 |
| Viéitez, JM | 1 |
| García-Alfonso, P | 1 |
| Calle, SG | 1 |
| Ortiz-Morales, MJ | 1 |
| Salud, A | 1 |
| Quintero, G | 1 |
| Lopez, C | 1 |
| Díaz-Rubio, E | 1 |
| Aranda, E | 1 |
| Hough, NE | 1 |
| Chapman, SJ | 1 |
| Flight, WG | 1 |
| Nong, S | 1 |
| Pan, X | 1 |
| Chen, K | 1 |
| Zhu, X | 1 |
| Evesque, L | 1 |
| Benezery, K | 1 |
| Follana, P | 1 |
| Tuan Falk, A | 1 |
| Doyen, J | 1 |
| Reure, J | 1 |
| Cavaglione, G | 1 |
| François, E | 2 |
| Zhao, Y | 1 |
| Xu, K | 1 |
| Liu, P | 1 |
| Bang, YJ | 1 |
| Kang, YK | 2 |
| Ng, M | 1 |
| Chung, HC | 1 |
| Wainberg, ZA | 1 |
| Gendreau, S | 1 |
| Chan, WY | 1 |
| Xu, N | 1 |
| Maslyar, D | 1 |
| Meng, R | 1 |
| Chau, I | 1 |
| Ajani, JA | 2 |
| Sun, Y | 1 |
| Wu, X | 1 |
| Zhang, Y | 1 |
| Lin, H | 1 |
| Lu, X | 1 |
| Huang, Y | 1 |
| Chi, P | 1 |
| Pintova, S | 1 |
| Dharmupari, S | 1 |
| Moshier, E | 1 |
| Zubizarreta, N | 1 |
| Ang, C | 1 |
| Holcombe, RF | 1 |
| Spina, A | 1 |
| Sorvillo, L | 1 |
| Chiosi, E | 1 |
| Esposito, A | 1 |
| Di Maiolo, F | 1 |
| Sapio, L | 1 |
| Caraglia, M | 1 |
| Naviglio, S | 1 |
| Schaller, G | 1 |
| El-Hadaad, HA | 1 |
| Wahba, HA | 1 |
| Bian, L | 1 |
| Wang, T | 2 |
| Zhang, S | 1 |
| Jiang, Z | 1 |
| Kuranishi, F | 1 |
| Ohno, T | 2 |
| Kundel, Y | 1 |
| Nasser, NJ | 1 |
| Purim, O | 1 |
| Yerushalmi, R | 1 |
| Fenig, E | 1 |
| Pfeffer, RM | 1 |
| Stemmer, SM | 1 |
| Rizel, S | 1 |
| Symon, Z | 1 |
| Kaufman, B | 1 |
| Sulkes, A | 2 |
| Brenner, B | 1 |
| Kajiura, S | 1 |
| Hosokawa, A | 1 |
| Yoshita, H | 1 |
| Ueda, Y | 1 |
| Ueda, A | 2 |
| Mihara, H | 1 |
| Ando, T | 1 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Oashi, K | 1 |
| Tsutsumida, A | 1 |
| Namikawa, K | 1 |
| Tanaka, R | 2 |
| Omata, W | 1 |
| Yamamoto, Y | 4 |
| Yamazaki, N | 1 |
| De Iuliis, F | 1 |
| Salerno, G | 1 |
| Taglieri, L | 1 |
| Vicinanza, R | 1 |
| Lanza, R | 1 |
| Scarpa, S | 1 |
| Hsieh, IS | 1 |
| Yang, RS | 1 |
| Fu, WM | 1 |
| Duran, AO | 1 |
| Karaca, H | 1 |
| Besiroglu, M | 1 |
| Bayoglu, IV | 1 |
| Menekse, S | 1 |
| Yapici, HS | 1 |
| Yazilitas, D | 1 |
| Bahceci, A | 1 |
| Uysal, M | 1 |
| Sevinc, A | 1 |
| Hacibekiroglu, I | 1 |
| Aksoy, A | 1 |
| Tanriverdi, O | 1 |
| Arpaci, E | 1 |
| Inanc, M | 1 |
| Dane, F | 1 |
| Ozkan, M | 1 |
| Noguchi, Y | 1 |
| Mitani, T | 1 |
| Kawara, H | 1 |
| Tokuyama, Y | 1 |
| Tamura, Y | 1 |
| Uchiyama, K | 1 |
| Shimizu, Y | 1 |
| Lee, A | 1 |
| Go, SI | 1 |
| Lee, WS | 1 |
| Lee, US | 1 |
| Kim, MJ | 1 |
| Kang, MH | 1 |
| Lee, GW | 1 |
| Kim, HG | 1 |
| Kang, JH | 1 |
| Jeon, KN | 1 |
| Cho, JM | 1 |
| Lee, JH | 1 |
| Cho, H | 2 |
| Nishiike, S | 1 |
| Takenaka, Y | 1 |
| Nakahara, S | 1 |
| Yasui, T | 1 |
| Hanamoto, A | 1 |
| Inohara, H | 1 |
| So, S | 1 |
| Kido, M | 1 |
| Fukumoto, T | 1 |
| Takebe, A | 1 |
| Tanaka, M | 2 |
| Kinoshita, H | 2 |
| Kuramitsu, K | 1 |
| Tsugawa, D | 1 |
| Fukushima, K | 1 |
| Urade, T | 1 |
| Yoshida, T | 2 |
| Asari, S | 1 |
| Okazaki, T | 1 |
| Shinzeki, M | 1 |
| Matsumoto, I | 1 |
| Ajiki, T | 1 |
| Ku, Y | 1 |
| Turkeli, M | 1 |
| Aldemir, MN | 1 |
| Cayir, K | 1 |
| Simsek, M | 1 |
| Bilici, M | 1 |
| Tekin, SB | 1 |
| Yildirim, N | 1 |
| Bilen, N | 1 |
| Makas, I | 1 |
| Schott, S | 2 |
| Vallet, S | 1 |
| Tower, RJ | 2 |
| Noor, S | 1 |
| Tiwari, S | 2 |
| Schem, C | 2 |
| Busch, C | 1 |
| Shinomiya, H | 1 |
| Hasegawa, S | 1 |
| Yamashita, D | 1 |
| Ejima, Y | 1 |
| Kenji, Y | 1 |
| Otsuki, N | 1 |
| Kiyota, N | 1 |
| Sakakibara, S | 1 |
| Nomura, T | 2 |
| Hashikawa, K | 1 |
| Kohmura, E | 1 |
| Sasaki, R | 1 |
| Nibu, K | 1 |
| De Divitiis, C | 1 |
| Cassata, A | 1 |
| Nasti, G | 1 |
| Ottaiano, A | 1 |
| Nappi, A | 1 |
| Barretta, ML | 1 |
| Iaffaioli, RV | 1 |
| Liang, Y | 1 |
| Bu, JG | 1 |
| Cheng, JL | 1 |
| Gao, WW | 1 |
| Xu, YC | 1 |
| Feng, J | 2 |
| Chen, BY | 1 |
| Liang, WC | 1 |
| Chen, KQ | 1 |
| Zhang, L | 1 |
| Wu, C | 1 |
| Hoffman, RM | 1 |
| Kotecki, N | 1 |
| Hiret, S | 1 |
| Etienne, PL | 1 |
| Penel, N | 1 |
| Tresch, E | 1 |
| Galais, MP | 1 |
| Ben Abdelghani, M | 1 |
| Michel, P | 1 |
| Dahan, L | 1 |
| Ghiringelli, F | 1 |
| Bedenne, L | 1 |
| Samalin, E | 1 |
| Piessen, G | 1 |
| Bennouna, J | 1 |
| Peugniez, C | 1 |
| El Hajbi, F | 1 |
| Clisant, S | 1 |
| Kramar, A | 1 |
| Mariette, C | 1 |
| Adenis, A | 1 |
| Takenoya, T | 1 |
| Nishimura, Y | 2 |
| Asayama, M | 1 |
| Takano, M | 1 |
| Mori, Y | 2 |
| Ishikawa, H | 1 |
| Nishizawa, Y | 1 |
| Fukuda, T | 1 |
| Kazama, S | 1 |
| Amikura, K | 1 |
| Kurozumi, M | 1 |
| Kawashima, Y | 1 |
| Tanaka, Y | 4 |
| Sakamoto, H | 1 |
| Koca, D | 1 |
| Ozdemir, O | 1 |
| Demir, D | 1 |
| Akdeniz, H | 1 |
| Kurt, M | 1 |
| Sarman, H | 1 |
| Bayram, R | 1 |
| Benek, SB | 1 |
| Huang, CW | 1 |
| Yeh, YS | 1 |
| Ma, CJ | 1 |
| Tsai, HL | 1 |
| Chen, CW | 1 |
| Huang, MY | 1 |
| Lu, CY | 1 |
| Wu, JY | 1 |
| Wang, JY | 1 |
| Kneissl, P | 1 |
| Rambow, AC | 1 |
| Campbell, GM | 1 |
| Desel, C | 1 |
| Damm, T | 1 |
| Heilmann, T | 1 |
| Fuchs, S | 1 |
| Zuhayra, M | 1 |
| Trauzold, A | 1 |
| Glüer, CC | 1 |
| Takeyama, H | 1 |
| Shimada, T | 1 |
| Kinoshita, S | 1 |
| Uchida, K | 1 |
| Garcia, JR | 1 |
| Pérez, C | 1 |
| Bassa, P | 1 |
| Capdevila, L | 1 |
| Ramos, F | 1 |
| Valenti, V | 1 |
| Leong, SS | 1 |
| Wee, J | 1 |
| Rajan, S | 1 |
| Toh, CK | 1 |
| Lim, WT | 1 |
| Hee, SW | 1 |
| Tay, MH | 1 |
| Poon, D | 1 |
| Tan, EH | 1 |
| Lee, JL | 1 |
| Kang, HJ | 1 |
| Lee, KH | 1 |
| Zang, DY | 1 |
| Ryoo, BY | 1 |
| Kim, JG | 1 |
| Park, SR | 1 |
| Kang, WK | 2 |
| Shin, DB | 1 |
| Ryu, MH | 1 |
| Chang, HM | 1 |
| Kim, TW | 1 |
| Baek, JH | 1 |
| Min, YJ | 1 |
| Osako, T | 1 |
| Ito, Y | 3 |
| Ushijima, M | 1 |
| Takahashi, S | 6 |
| Tokudome, N | 3 |
| Sugihara, T | 2 |
| Iwase, T | 2 |
| Matsuura, M | 2 |
| Hatake, K | 2 |
| Mizoshita, T | 1 |
| Kataoka, H | 1 |
| Kubota, E | 1 |
| Okamoto, Y | 1 |
| Shimura, T | 1 |
| Wada, T | 1 |
| Ogasawara, N | 1 |
| Sasaki, M | 1 |
| Kamiya, T | 1 |
| Joh, T | 1 |
| Osaki, Y | 1 |
| Harshman, LC | 1 |
| Li, M | 1 |
| Srinivas, S | 1 |
| Fornaro, L | 1 |
| Bursi, S | 1 |
| Loupakis, F | 1 |
| Vasile, E | 1 |
| Antonuzzo, A | 1 |
| Chiara, S | 1 |
| Pfanner, E | 1 |
| Di Paolo, A | 1 |
| Bocci, G | 1 |
| Del Tacca, M | 1 |
| Falcone, A | 1 |
| Recchia, F | 1 |
| Candeloro, G | 1 |
| Necozione, S | 1 |
| Bratta, M | 1 |
| Bisegna, R | 1 |
| Rea, S | 1 |
| Chayahara, N | 1 |
| Tamura, T | 1 |
| Yamamori, M | 1 |
| Kadowaki, Y | 1 |
| Okuno, T | 1 |
| Miki, I | 1 |
| Tsuda, M | 1 |
| Nishisaki, H | 1 |
| Maeda, T | 1 |
| Inoue, Y | 1 |
| Okumura, K | 1 |
| Azuma, T | 1 |
| Kasuga, M | 1 |
| Sakaeda, T | 1 |
| Hirai, M | 1 |
| Lam, MG | 1 |
| Bosma, TB | 1 |
| van Rijk, PP | 1 |
| Zonnenberg, BA | 1 |
| Daliani, DD | 1 |
| Tannir, NM | 1 |
| Papandreou, CN | 1 |
| Wang, X | 1 |
| Swisher, S | 1 |
| Wood, CG | 1 |
| Swanson, DA | 1 |
| Logothetis, CJ | 3 |
| Jonasch, E | 1 |
| Waters, SH | 1 |
| Gillibrand, A | 1 |
| Berry, H | 1 |
| Kumar, S | 1 |
| Velikova, G | 1 |
| Dodwell, DJ | 1 |
| Perren, TJ | 1 |
| Zhang, DK | 1 |
| Su, XD | 1 |
| Lin, P | 1 |
| Long, H | 1 |
| Fu, JH | 1 |
| Zhang, LJ | 1 |
| Ma, GW | 1 |
| Rong, TH | 1 |
| Wong, AL | 1 |
| Chou, N | 1 |
| Lee, KM | 1 |
| Ang, BW | 1 |
| Cheng, CL | 1 |
| Lee, SC | 1 |
| Takashima, A | 1 |
| Shirao, K | 1 |
| Hirashima, Y | 1 |
| Takahari, D | 1 |
| Okita, NT | 1 |
| Nakajima, TE | 1 |
| Kato, K | 1 |
| Hamaguchi, T | 1 |
| Yamada, Y | 1 |
| Shimada, Y | 2 |
| Song, B | 1 |
| Wang, Y | 1 |
| Xi, Y | 1 |
| Kudo, K | 1 |
| Bruheim, S | 1 |
| Botchkina, GI | 1 |
| Gavin, E | 1 |
| Wan, Y | 1 |
| Formentini, A | 1 |
| Kornmann, M | 1 |
| Fodstad, O | 1 |
| Ju, J | 1 |
| Amari, M | 1 |
| Ishida, T | 1 |
| Takeda, M | 1 |
| Ohuchi, N | 1 |
| Wardley, AM | 1 |
| Pivot, X | 1 |
| Morales-Vasquez, F | 1 |
| Zetina, LM | 1 |
| de Fátima Dias Gaui, M | 1 |
| Reyes, DO | 1 |
| Jassem, J | 1 |
| Barton, C | 1 |
| Button, P | 1 |
| Hersberger, V | 1 |
| Torres, AA | 1 |
| Mallik, S | 1 |
| Gupta, S | 1 |
| Munshi, A | 1 |
| Zhou, J | 1 |
| Zhang, WM | 1 |
| Chen, H | 1 |
| Xie, B | 1 |
| Zheng, JH | 1 |
| Xu, ZY | 1 |
| Lin, JR | 1 |
| Tanaka, T | 2 |
| Tanino, H | 1 |
| Hirai, I | 1 |
| Hata, K | 3 |
| Maebeya, S | 1 |
| Oota, F | 1 |
| Miki, Y | 1 |
| Umeda, T | 1 |
| Abe, H | 1 |
| Shimizu, T | 1 |
| Mori, T | 1 |
| Kubota, Y | 1 |
| Kawai, Y | 1 |
| Kurumi, Y | 1 |
| Tani, T | 2 |
| Walter, B | 1 |
| Rogenhofer, S | 1 |
| Vogelhuber, M | 1 |
| Berand, A | 1 |
| Wieland, WF | 1 |
| Andreesen, R | 2 |
| Reichle, A | 1 |
| Honda, M | 1 |
| Miura, A | 1 |
| Izumi, Y | 1 |
| Kato, T | 1 |
| Ryotokuji, T | 1 |
| Monma, K | 2 |
| Fujiwara, J | 1 |
| Egashira, H | 1 |
| Nemoto, T | 1 |
| Schneiders, FL | 1 |
| van den Berg, HP | 1 |
| Peters, GJ | 1 |
| Verheul, HM | 1 |
| van der Vliet, HJ | 1 |
| Mao, FJ | 1 |
| Sidorova, JM | 1 |
| Lauper, JM | 1 |
| Emond, MJ | 1 |
| Monnat, RJ | 1 |
| Tagawa, ST | 1 |
| Milowsky, MI | 1 |
| Jeske, S | 1 |
| Mazumdar, M | 1 |
| Kung, S | 1 |
| Sung, M | 1 |
| Lehrer, D | 1 |
| Matulich, D | 1 |
| Selzer, J | 1 |
| Wright, JJ | 1 |
| Nanus, DM | 1 |
| Fantini, M | 1 |
| Gianni, L | 1 |
| Tassinari, D | 1 |
| Nicoletti, S | 1 |
| Possenti, C | 1 |
| Drudi, F | 1 |
| Sintini, M | 1 |
| Bagli, L | 1 |
| Ravaioli, A | 1 |
| Kwon, HC | 1 |
| Kim, MC | 1 |
| Kim, KH | 1 |
| Jang, JS | 1 |
| Oh, SY | 1 |
| Kim, SH | 1 |
| Kwon, KA | 1 |
| Lee, S | 1 |
| Lee, HS | 1 |
| Kim, HJ | 1 |
| Hata, T | 1 |
| Fujino, S | 1 |
| Yanagawa, T | 1 |
| Kitahara, T | 1 |
| Munakata, K | 1 |
| Watanabe, N | 1 |
| Takamoto, K | 1 |
| Miyake, M | 1 |
| Kawanishi, K | 1 |
| Shimizu, J | 1 |
| Ikeda, K | 1 |
| Fujita, J | 1 |
| Iwazawa, T | 1 |
| Akagi, K | 1 |
| Douno, K | 1 |
| Kitada, M | 1 |
| Shimano, T | 1 |
| Rosenberg, M | 1 |
| Castagno, A | 1 |
| Nadal, J | 1 |
| Rosales, A | 1 |
| Pueyrredon, EP | 1 |
| Patané, AK | 1 |
| Yu, J | 1 |
| DI, Lj | 1 |
| Song, Gh | 1 |
| Che, L | 1 |
| Jiang, Hf | 1 |
| Zhu, Yl | 1 |
| Liang, X | 1 |
| Jia, J | 1 |
| Yang, Hb | 1 |
| Wang, Xl | 1 |
| Zhou, Xn | 1 |
| Ren, J | 1 |
| Kim, ST | 1 |
| Choi, YJ | 1 |
| Park, KH | 1 |
| Oh, SC | 1 |
| Seo, JH | 1 |
| Shin, SW | 1 |
| Kim, JS | 1 |
| Kim, YH | 2 |
| Lin, PH | 1 |
| Chiu, CF | 1 |
| Lu, YS | 1 |
| Ferreira, A | 1 |
| Vieira, C | 1 |
| Rodrigues, A | 1 |
| Pereira, D | 1 |
| Rodrigues, H | 1 |
| Dávila, C | 1 |
| Bento, S | 1 |
| Kubo, N | 1 |
| Takeuchi, N | 1 |
| Nakayama, A | 1 |
| Ogiwara, H | 1 |
| Tsujimoto, K | 1 |
| Ito, N | 1 |
| Koiwai, K | 1 |
| Delpeuch, A | 1 |
| Leveque, D | 1 |
| Rob, L | 1 |
| Bergerat, JP | 1 |
| Chen, SZ | 1 |
| Chen, XM | 1 |
| Ding, Y | 1 |
| Wang, XC | 1 |
| Zhang, F | 1 |
| Mo, KL | 1 |
| Sakamoto, T | 1 |
| Oyamatsu, M | 1 |
| Sato, K | 2 |
| Hinchliffe, E | 1 |
| Allcock, RL | 1 |
| Mansoor, W | 1 |
| Myers, MA | 1 |
| Hirano, G | 1 |
| Sakurai, K | 1 |
| Sohda, T | 1 |
| Kunimoto, H | 1 |
| Yotsumoto, K | 1 |
| Fukunaga, A | 1 |
| Iwashita, H | 1 |
| Ueda, S | 1 |
| Yokoyama, K | 1 |
| Morihara, D | 1 |
| Takeyama, Y | 1 |
| Sakamoto, M | 1 |
| Irie, M | 1 |
| Iwata, K | 1 |
| Shakado, S | 1 |
| Sakisaka, S | 1 |
| Roldán, AM | 1 |
| Núñez, NF | 1 |
| Grande, E | 1 |
| García, AÁ | 1 |
| Antón-Aparicio, LM | 1 |
| Yi, JH | 1 |
| Lee, J | 2 |
| Park, SH | 1 |
| Park, JO | 1 |
| Yim, DS | 1 |
| Park, YS | 1 |
| Lim, HY | 1 |
| Shatz, M | 1 |
| Menendez, D | 1 |
| Resnick, MA | 1 |
| Novarino, AM | 1 |
| Satolli, MA | 1 |
| Chiappino, I | 1 |
| Giacobino, A | 1 |
| Napoletano, R | 1 |
| Ceccarelli, M | 1 |
| Ciccone, G | 1 |
| Schena, M | 1 |
| Bertetto, O | 1 |
| Ciuffreda, L | 1 |
| Dogan, M | 1 |
| Karabulut, HG | 1 |
| Tukun, A | 1 |
| Demirkazik, A | 1 |
| Utkan, G | 1 |
| Yalcin, B | 1 |
| Dincol, D | 1 |
| Akbulut, H | 1 |
| Icli, F | 1 |
| Weinreich, J | 1 |
| Schott, TC | 1 |
| Königsrainer, I | 1 |
| Küper, M | 1 |
| Königsrainer, A | 1 |
| Schott, H | 1 |
| Inal, A | 1 |
| Kaplan, MA | 1 |
| Kuçukoner, M | 1 |
| Urakci, Z | 1 |
| Guven, M | 1 |
| Nas, N | 1 |
| Yunce, M | 1 |
| Işikdogan, A | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Weiderpass, E | 1 |
| Jin, Y | 1 |
| Ye, X | 1 |
| Shao, L | 1 |
| Lin, BC | 1 |
| He, CX | 1 |
| Zhang, BB | 1 |
| Zhang, YP | 1 |
| Masuda, T | 1 |
| Uetake, H | 1 |
| Yamauchi, S | 1 |
| Okazaki, S | 1 |
| Matsuyama, T | 1 |
| Ishiguro, M | 1 |
| Ishikawa, T | 2 |
| Kobayashi, H | 1 |
| Iida, S | 1 |
| Higuchi, T | 1 |
| Sugihara, K | 1 |
| Camidge, R | 1 |
| Price, A | 1 |
| Heidemann, E | 1 |
| Stoeger, H | 1 |
| Souchon, R | 1 |
| Hirschmann, WD | 1 |
| Bodenstein, H | 1 |
| Oberhoff, C | 1 |
| Fischer, JT | 1 |
| Schulze, M | 1 |
| Clemens, M | 1 |
| Mahlke, M | 1 |
| König, M | 1 |
| Scharl, A | 1 |
| Fehnle, K | 1 |
| Kaufmann, M | 1 |
| Mori, K | 1 |
| Chiba, N | 2 |
| Yonekawa, H | 1 |
| Venturini, M | 1 |
| Durando, A | 1 |
| Garrone, O | 1 |
| Colozza, MA | 1 |
| Contu, A | 1 |
| Stevani, I | 1 |
| Genta, F | 1 |
| Bighin, C | 1 |
| Lambiase, A | 1 |
| Del Mastro, L | 1 |
| Sagawa, T | 1 |
| Tsuji, Y | 1 |
| Takayanagi, N | 1 |
| Hirayama, Y | 1 |
| Sakamaki, S | 1 |
| Chiba, H | 1 |
| Iyama, S | 2 |
| Oku, T | 1 |
| Sato, Y | 1 |
| Takahashi, M | 3 |
| Takayama, T | 1 |
| Niitsu, Y | 1 |
| Hiraga, T | 2 |
| Tamura, D | 1 |
| Ikeda, F | 2 |
| Williams, PJ | 1 |
| Yoneda, T | 2 |
| DOWD, JE | 1 |
| DIPAOLO, JA | 1 |
| WATNE, AL | 1 |
| RIEHL, JL | 1 |
| BROWN, WJ | 1 |
| CAMMACK, KV | 1 |
| Abrams, TJ | 1 |
| Murray, LJ | 1 |
| Pesenti, E | 1 |
| Holway, VW | 1 |
| Colombo, T | 1 |
| Lee, LB | 1 |
| Cherrington, JM | 1 |
| Pryer, NK | 1 |
| Ramnaraine, M | 2 |
| Pan, W | 2 |
| Goblirsch, M | 1 |
| Lynch, C | 1 |
| Lewis, V | 1 |
| Orchard, P | 1 |
| Mantyh, P | 1 |
| Clohisy, DR | 2 |
| Ishii, Y | 1 |
| Nakayama, K | 1 |
| Itou, T | 1 |
| Abe, N | 1 |
| Mezawa, S | 1 |
| Homma, H | 1 |
| Doi, T | 1 |
| Akiyama, T | 1 |
| Murakami, K | 1 |
| Kogawa, K | 1 |
| Hirata, K | 2 |
| Kida, M | 1 |
| Murase, K | 1 |
| Schüll, B | 1 |
| Scheithauer, W | 2 |
| Kornek, GV | 2 |
| Fukuda, Y | 2 |
| Fujio, N | 1 |
| Takatori, H | 2 |
| Tsukazaki, T | 1 |
| Terakura, M | 2 |
| Mayumi, K | 2 |
| Koyama, I | 2 |
| Tsukazaki, Y | 2 |
| Osugi, H | 1 |
| Schuell, B | 1 |
| Laengle, F | 1 |
| Gruenberger, T | 1 |
| Penz, M | 1 |
| Karall, K | 1 |
| Depisch, D | 1 |
| Lang, F | 1 |
| Ohta, S | 1 |
| Takiuchi, H | 1 |
| Kawabe, S | 1 |
| Gotoh, M | 1 |
| Hirata, I | 1 |
| Katsu, K | 1 |
| Hongo, H | 1 |
| Fujita, K | 1 |
| Yagyu, T | 1 |
| Aihara, T | 1 |
| Murayama, M | 1 |
| Nakamura, E | 1 |
| Nozaki, H | 2 |
| Niida, M | 1 |
| Yasuoka, H | 1 |
| Nishimoto, Y | 2 |
| Watanabe, Y | 2 |
| Syouda, S | 1 |
| Kouno, T | 1 |
| Fukuhara, A | 1 |
| Nakagawa, K | 1 |
| Wei, J | 1 |
| Blum, S | 1 |
| Unger, M | 1 |
| Jarmy, G | 1 |
| Lamparter, M | 1 |
| Geishauser, A | 1 |
| Vlastos, GA | 1 |
| Chan, G | 1 |
| Fischer, KD | 1 |
| Rattat, D | 1 |
| Debatin, KM | 2 |
| Hatzopoulos, AK | 1 |
| Beltinger, C | 1 |
| Niemann, B | 1 |
| Rochlitz, C | 2 |
| Herrmann, R | 2 |
| Pless, M | 1 |
| Jiang, ZF | 1 |
| Song, ST | 1 |
| Zhang, SH | 1 |
| Shen, G | 1 |
| Yu, JX | 1 |
| Birtle, AJ | 1 |
| Newby, JC | 1 |
| Harland, SJ | 1 |
| Andreadis, C | 1 |
| Charalampidou, M | 1 |
| Diamantopoulos, N | 1 |
| Chouchos, N | 1 |
| Mouratidou, D | 1 |
| El-Mabhouh, A | 2 |
| Angelov, C | 1 |
| McEwan, A | 1 |
| Jia, G | 1 |
| Mercer, J | 1 |
| Mercer, JR | 1 |
| Brinkmann, OA | 1 |
| Bruns, F | 1 |
| Gosheger, G | 1 |
| Micke, O | 1 |
| Hertle, L | 1 |
| Mizuno, K | 1 |
| Togashi, T | 1 |
| Watanabe, K | 1 |
| Seki, K | 1 |
| Ohta, H | 1 |
| Kamimura, T | 1 |
| Nilsson, S | 1 |
| Strang, P | 1 |
| Ginman, C | 1 |
| Zimmermann, R | 1 |
| Edgren, M | 1 |
| Nordström, B | 1 |
| Ryberg, M | 1 |
| Kälkner, KM | 1 |
| Westlin, JE | 1 |
| Kitagaki, J | 1 |
| Fujimoto-Ouchi, K | 1 |
| Zhao, J | 1 |
| Jin, J | 1 |
| Zhang, X | 1 |
| Shi, M | 1 |
| Dai, J | 1 |
| Wu, M | 1 |
| Wang, R | 1 |
| Guo, Y | 1 |
| Matsuoka, T | 1 |
| Morikage, N | 1 |
| Kobayashi, T | 2 |
| Kuga, T | 1 |
| Nakayama, T | 1 |
| Fujii, Y | 1 |
| Cho, JY | 1 |
| Paik, YH | 1 |
| Chang, YS | 1 |
| Lee, SJ | 1 |
| Lee, DK | 1 |
| Song, SY | 1 |
| Chung, JB | 1 |
| Park, MS | 1 |
| Yu, JS | 1 |
| Yoon, DS | 1 |
| Malani, AK | 1 |
| Gupta, C | 1 |
| Rangineni, S | 1 |
| Gupta, V | 1 |
| Lin, CC | 1 |
| Hsu, CH | 1 |
| Huang, CY | 1 |
| Cheng, AL | 1 |
| Chen, J | 1 |
| Vogelzang, NJ | 1 |
| Pu, YS | 1 |
| Saeki, T | 2 |
| Kimura, T | 1 |
| Toi, M | 1 |
| Taguchi, T | 1 |
| Yeh, SA | 1 |
| Tang, Y | 1 |
| Lui, CC | 1 |
| Huang, EY | 1 |
| Cardinale, D | 1 |
| Colombo, A | 1 |
| Colombo, N | 1 |
| Vredenburgh, JJ | 1 |
| Madan, B | 1 |
| Coniglio, D | 1 |
| Ross, M | 2 |
| Broadwater, G | 1 |
| Niedzwiecki, D | 1 |
| Edwards, J | 1 |
| Marks, L | 1 |
| Vandemark, R | 1 |
| McDonald, C | 1 |
| Affronti, ML | 2 |
| Peters, WP | 1 |
| Lu, JI | 1 |
| Carhart, RL | 1 |
| Graziano, SL | 1 |
| Gajra, A | 1 |
| Khanfir, A | 1 |
| Frikha, M | 1 |
| Ghorbel, A | 1 |
| Karray, H | 1 |
| Drira, MM | 1 |
| Daoud, J | 1 |
| Beckermann, B | 1 |
| Kallifatidis, G | 1 |
| Liu, Z | 1 |
| Rittgen, W | 1 |
| Edler, L | 1 |
| Büchler, P | 1 |
| Büchler, MW | 1 |
| Friess, H | 1 |
| Herr, I | 1 |
| Shiiki, S | 1 |
| Sonoo, H | 2 |
| Seki, M | 1 |
| Hironou, M | 1 |
| Ookubo, S | 1 |
| Udagawa, K | 1 |
| Nakashima, K | 1 |
| Ikeda, M | 1 |
| Tanaka, K | 1 |
| Kurebayashi, J | 2 |
| Yoshidome, K | 1 |
| Imabun, S | 1 |
| Nakahara, M | 1 |
| Hiraoka, K | 1 |
| Yamagami, Y | 1 |
| Tsujimoto, M | 1 |
| Nakao, K | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Pons Sanz, V | 1 |
| Martínez Banaclocha, N | 1 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Guedin, P | 1 |
| Chasle, J | 1 |
| Blanc-Fournier, C | 1 |
| Lacroix, J | 1 |
| Nishizawa, T | 1 |
| Higuchi, H | 1 |
| Takaishi, H | 1 |
| Iizuka, H | 1 |
| Izumiya, M | 1 |
| Yamagishi, Y | 1 |
| Hisamatsu, T | 1 |
| Suzuki, H | 1 |
| Masaoka, T | 1 |
| Iwasaki, E | 1 |
| Nagata, H | 1 |
| Hibi, T | 1 |
| Satoh, D | 1 |
| Ninomiya, M | 1 |
| Umeoka, T | 1 |
| Harano, M | 1 |
| Sasaki, H | 1 |
| Aoki, H | 1 |
| Onoda, T | 1 |
| Shiozaki, Y | 1 |
| Ohno, S | 1 |
| Higaki, K | 1 |
| Takakura, N | 1 |
| Suzuki, M | 1 |
| Wang, CT | 1 |
| Cao, KJ | 1 |
| Xie, GF | 1 |
| Huang, PY | 1 |
| Gutova, M | 1 |
| Najbauer, J | 1 |
| Gevorgyan, A | 1 |
| Metz, MZ | 1 |
| Weng, Y | 1 |
| Shih, CC | 1 |
| Aboody, KS | 1 |
| Huang, TW | 1 |
| Wang, CH | 1 |
| Hsieh, CB | 1 |
| Akahane, T | 1 |
| Chiba, T | 1 |
| Yano, H | 1 |
| Hashimoto, Y | 1 |
| Neri, B | 1 |
| Pantaleo, P | 1 |
| Giommoni, E | 1 |
| Grifoni, R | 1 |
| Paoletti, C | 1 |
| Rotella, V | 1 |
| Pantalone, D | 1 |
| Taddei, A | 1 |
| Mercatelli, A | 1 |
| Tonelli, P | 1 |
| Yap, YS | 1 |
| Kendall, A | 1 |
| Walsh, G | 1 |
| Banerji, U | 1 |
| Johnston, SR | 1 |
| Smith, IE | 1 |
| O'Brien, M | 1 |
| Wang, XX | 1 |
| Zhou, ZM | 1 |
| Yuan, ZY | 1 |
| Zhang, DS | 1 |
| Shi, YX | 1 |
| Jiang, WQ | 1 |
| Fontana, S | 1 |
| Ghilardi, R | 1 |
| Barbaglio, A | 1 |
| Amaddeo, P | 1 |
| Faldi, F | 1 |
| Pericotti, S | 1 |
| Yamamoto, D | 1 |
| Iwase, S | 1 |
| Kitamura, K | 1 |
| Odagiri, H | 1 |
| Yamamoto, C | 1 |
| Nagumo, Y | 1 |
| Masuda, N | 1 |
| Kato, S | 2 |
| Yasuda, K | 1 |
| Nishino, Y | 1 |
| Ohori, H | 1 |
| Yamaura, G | 1 |
| Ohtsuka, K | 1 |
| Kakudo, Y | 1 |
| Shimodaira, H | 1 |
| Sakayori, M | 1 |
| Suzuki, T | 2 |
| Murakawa, Y | 1 |
| Gamoh, M | 1 |
| Shibata, H | 1 |
| Yoshioka, T | 1 |
| Ishioka, C | 1 |
| Chen, L | 1 |
| Fan, Y | 1 |
| Lang, RG | 1 |
| Guo, XJ | 1 |
| Sun, YL | 1 |
| Fu, L | 1 |
| Fujita, H | 1 |
| Sueyoshi, S | 1 |
| Sasahara, H | 1 |
| Mori, N | 1 |
| Nagano, T | 1 |
| Yamana, H | 1 |
| Shirouzu, K | 1 |
| McLean, SR | 1 |
| Shousha, S | 1 |
| Francis, N | 1 |
| Lim, A | 1 |
| Eccles, S | 1 |
| Nathan, M | 1 |
| Brock, CS | 1 |
| Palmieri, C | 1 |
| Crump, M | 1 |
| Gluck, S | 1 |
| Tu, D | 1 |
| Stewart, D | 1 |
| Levine, M | 1 |
| Kirkbride, P | 1 |
| Dancey, J | 1 |
| O'Reilly, S | 1 |
| Shore, T | 1 |
| Couban, S | 1 |
| Girouard, C | 1 |
| Marlin, S | 1 |
| Shepherd, L | 1 |
| Pritchard, KI | 1 |
| Ishizuka, S | 1 |
| Morikawa, T | 1 |
| Yoshida, K | 1 |
| Nobuhisa, T | 1 |
| Endo, Y | 1 |
| Watanabe, T | 3 |
| Matsumoto, Y | 1 |
| Doi, Y | 1 |
| Yamada, T | 1 |
| Kai, K | 1 |
| Nakashima, A | 2 |
| Nagahiro, I | 1 |
| Sato, S | 1 |
| Nabeyama, A | 1 |
| Fabi, A | 1 |
| Metro, G | 1 |
| Papaldo, P | 1 |
| Mottolese, M | 1 |
| Melucci, E | 1 |
| Carlini, P | 1 |
| Sperduti, I | 1 |
| Russillo, M | 1 |
| Gelibter, A | 1 |
| Ferretti, G | 1 |
| Tomao, S | 1 |
| Milella, M | 1 |
| Cognetti, F | 1 |
| Inoue, S | 1 |
| Inoue, M | 1 |
| Takahashi, H | 1 |
| Inoue, A | 1 |
| Kunitomo, K | 1 |
| Fujii, H | 1 |
| Burris, HA | 1 |
| Boeck, S | 1 |
| Wilkowski, R | 1 |
| Bruns, CJ | 1 |
| Issels, RD | 1 |
| Schulz, C | 1 |
| Moosmann, N | 1 |
| Laessig, D | 1 |
| Haas, M | 1 |
| Golf, A | 1 |
| Heinemann, V | 1 |
| Hess, D | 1 |
| Koberle, D | 1 |
| Thurlimann, B | 1 |
| Pagani, O | 1 |
| Schonenberger, A | 1 |
| Mattmann, S | 1 |
| Rauch, D | 1 |
| Schuller, JC | 1 |
| Ballabeni, P | 1 |
| Ribi, K | 1 |
| Kristensen, B | 1 |
| Ejlertsen, B | 1 |
| Mouridsen, HT | 1 |
| Jensen, MB | 1 |
| Andersen, J | 1 |
| Bjerregaard, B | 1 |
| Cold, S | 1 |
| Edlund, P | 1 |
| Ewertz, M | 1 |
| Kamby, C | 1 |
| Lindman, H | 1 |
| Nordenskjöld, B | 1 |
| Bergh, J | 1 |
| Shigekawa, T | 1 |
| Takeuchi, H | 1 |
| Misumi, M | 1 |
| Matsuura, K | 1 |
| Sano, H | 1 |
| Fujiuchi, N | 1 |
| Okubo, K | 1 |
| Osaki, A | 1 |
| Aogi, K | 1 |
| Takeuchi, S | 3 |
| Akahoshi, Y | 2 |
| Kasai, C | 1 |
| Beaufort, F | 1 |
| Gölles, M | 1 |
| Evans, RG | 1 |
| Burgert, EO | 1 |
| Gilchrist, GS | 1 |
| Smithson, WA | 1 |
| Pritchard, DJ | 1 |
| Bruckman, JE | 1 |
| Barone, RM | 1 |
| Byfield, JE | 1 |
| Goldfarb, PB | 1 |
| Frankel, S | 1 |
| Ginn, C | 1 |
| Greer, S | 1 |
| Weltz, MD | 1 |
| Perry, DJ | 1 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Legha, SS | 2 |
| Blumenschein, GR | 4 |
| Hortobagyi, GN | 4 |
| Buzdar, AU | 4 |
| Vincent-Joyeux, F | 1 |
| Bontoux, D | 1 |
| Alcalay, M | 1 |
| Daban, A | 1 |
| Vincent, D | 1 |
| Spehn, J | 1 |
| Beyer, JH | 1 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 1 |
| Abel, U | 1 |
| Citrin, DL | 1 |
| Elson, P | 1 |
| DeWys, WD | 1 |
| Samuels, ML | 2 |
| von Eschenbach, AC | 2 |
| Trindade, A | 2 |
| Ogden, S | 1 |
| Grant, C | 1 |
| Johnson, DE | 3 |
| Voznyĭ, EK | 1 |
| Besova, NS | 1 |
| Kurkina, TV | 1 |
| Al'tshtuller, IuB | 1 |
| Eisenkraft, S | 1 |
| Huben, RP | 1 |
| Pontes, JE | 1 |
| Pinnamaneni, K | 1 |
| Yap, HY | 1 |
| Distefano, A | 1 |
| Cadman, EC | 1 |
| Glick, JH | 1 |
| Cross, J | 1 |
| Horton, J | 1 |
| Taylor, SG | 1 |
| Dymarskiĭ, LIu | 1 |
| Sanchakova, AV | 1 |
| Aleksandrova, GI | 1 |
| Trishkina, EA | 1 |
| Salvati, F | 1 |
| Pupillo, M | 1 |
| DeMartini, AL | 1 |
| Smalley, RV | 4 |
| Lefante, J | 1 |
| Bartolucci, A | 2 |
| Carpenter, J | 2 |
| Vogel, C | 2 |
| Krauss, S | 2 |
| Israel, L | 3 |
| Breau, JL | 2 |
| Aguilera, J | 1 |
| DeLuca, SA | 1 |
| Castronovo, FP | 1 |
| Rhea, JT | 1 |
| Servadio, C | 1 |
| Mukamel, E | 1 |
| Lurie, H | 1 |
| Nissenkorn, I | 1 |
| Valagussa, P | 2 |
| Tess, JD | 1 |
| Rossi, A | 2 |
| Tancini, G | 1 |
| Banfi, A | 1 |
| Bonadonna, G | 3 |
| Dalley, DN | 1 |
| Levi, JA | 2 |
| Aroney, RS | 1 |
| Woods, RL | 1 |
| Fox, RM | 1 |
| Tattersall, MH | 1 |
| Brodie, GN | 1 |
| Scogna, DM | 1 |
| Malmud, LS | 1 |
| Abe, O | 1 |
| Izuo, M | 1 |
| Enomoto, K | 1 |
| Kubo, K | 1 |
| Koyama, H | 2 |
| Sakai, K | 1 |
| Terasawa, T | 1 |
| Tominaga, T | 2 |
| Nomura, Y | 2 |
| Muss, HB | 1 |
| Howard, V | 1 |
| Richards, F | 1 |
| White, DR | 1 |
| Jackson, DV | 1 |
| Cooper, MR | 1 |
| Stuart, JJ | 1 |
| Resnick, MI | 1 |
| Brodkin, R | 1 |
| Spurr, CL | 1 |
| Libshitz, HI | 1 |
| Bitran, JD | 1 |
| Bekerman, C | 1 |
| Desser, RK | 1 |
| Jones, MA | 1 |
| Williams, G | 1 |
| Dreicer, R | 1 |
| Forest, PK | 1 |
| Williams, RD | 1 |
| Moriyama, A | 1 |
| Murata, I | 1 |
| Kuroda, T | 1 |
| Yoshikawa, I | 1 |
| Tabaru, A | 1 |
| Ogami, Y | 1 |
| Otsuki, M | 1 |
| Yagoda, A | 2 |
| Petrylak, D | 1 |
| Jardines, L | 1 |
| Callans, LS | 1 |
| Torosian, MH | 1 |
| Hietanen, P | 1 |
| Blomqvist, C | 2 |
| Wasenius, VM | 1 |
| Niskanen, E | 1 |
| Franssila, K | 1 |
| Nordling, S | 1 |
| Kattan, J | 1 |
| Culine, S | 1 |
| Theodore, C | 1 |
| Droz, JP | 1 |
| Shimozuma, K | 1 |
| Ohta, K | 1 |
| Kiyono, T | 1 |
| Bellman, B | 1 |
| Gregory, NA | 1 |
| Silvers, D | 1 |
| Fountain, KS | 1 |
| Zhang, GJ | 1 |
| Adachi, I | 3 |
| Yin, DF | 1 |
| Narabayashi, M | 2 |
| Tokue, Y | 1 |
| Kaneko, A | 1 |
| Tsuda, H | 1 |
| Abe, K | 1 |
| Goldhirsch, A | 1 |
| Gelber, RD | 1 |
| Price, KN | 1 |
| Castiglione, M | 1 |
| Coates, AS | 1 |
| Rudenstam, CM | 1 |
| Collins, J | 1 |
| Lindtner, J | 1 |
| Hacking, A | 1 |
| Marini, G | 1 |
| Satoh, Y | 1 |
| Une, Y | 1 |
| Fujisawa, J | 1 |
| Uchino, J | 1 |
| Sakai, H | 1 |
| Minami, Y | 1 |
| Kanetake, H | 1 |
| Saito, Y | 1 |
| Fukami, A | 1 |
| Lamar, RE | 1 |
| Greco, FA | 1 |
| Johnson, DH | 2 |
| Murphy, PB | 1 |
| Hainsworth, JD | 1 |
| Louvet, C | 1 |
| de Gramont, A | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Varette, C | 1 |
| Soubrane, D | 1 |
| Marpeau, L | 1 |
| Pigné, A | 1 |
| Guillot, T | 1 |
| Krulik, M | 1 |
| Zhou, JC | 1 |
| Anai, H | 1 |
| Muranaka, T | 1 |
| Takeo, S | 1 |
| Maekawa, S | 1 |
| Ikejiri, K | 1 |
| Yakabe, S | 1 |
| Furuyama, M | 1 |
| Saku, M | 1 |
| Ishikawa, A | 1 |
| Nakajima, N | 1 |
| Ozawa, M | 1 |
| Matsuda, M | 2 |
| Ito, K | 1 |
| Suzuki, K | 1 |
| Toyama, K | 1 |
| Ehlinger, P | 1 |
| Peeters, LC | 1 |
| Servais, J | 1 |
| Fossion, E | 1 |
| Wozniak, AJ | 1 |
| Blumenstein, BA | 1 |
| Crawford, ED | 1 |
| Boileau, M | 1 |
| Rivkin, SE | 1 |
| Fletcher, WS | 2 |
| Yano, M | 1 |
| Kume, K | 1 |
| Ono, E | 1 |
| Wakasugi, K | 1 |
| Matsuzaka, T | 1 |
| Fujinaga, H | 1 |
| Ohmori, Y | 1 |
| Toki, T | 1 |
| Okazaki, Y | 1 |
| Ogoshi, S | 1 |
| Ogawa, Y | 1 |
| Yumoto, Y | 2 |
| Okuda, T | 2 |
| Shimizu, S | 1 |
| Kawase, K | 1 |
| Risteli, L | 1 |
| Risteli, J | 1 |
| Virkkunen, P | 1 |
| Sarna, S | 1 |
| Elomaa, I | 1 |
| Malacarne, P | 1 |
| Maestri, A | 1 |
| DiPaola, RS | 1 |
| Kaufman, A | 1 |
| Mikhail, MM | 1 |
| Ohta, J | 1 |
| Maruiwa, M | 1 |
| Noutomi, M | 1 |
| Tokuhara, K | 1 |
| Inutsuka, K | 1 |
| Purdy, MH | 1 |
| Body, JJ | 1 |
| Gabra, H | 1 |
| Cameron, DA | 1 |
| Lee, LE | 1 |
| Mackay, J | 1 |
| Leonard, RC | 1 |
| Itoshima, T | 1 |
| Yamamoto, T | 1 |
| Kasamatsu, T | 1 |
| Fujino, H | 1 |
| Yamamoto, H | 1 |
| Morita, Y | 1 |
| Kodama, M | 1 |
| Hara, S | 1 |
| Hashizume, S | 1 |
| Itoyanagi, N | 1 |
| Ayabe, H | 1 |
| Tagawa, Y | 1 |
| Tsuji, H | 1 |
| Oka, T | 1 |
| Yamamoto, S | 1 |
| Shinguu, H | 1 |
| Tou, K | 1 |
| Tooyama, H | 1 |
| Yamazumi, K | 1 |
| Yen, CC | 1 |
| Tung, SL | 1 |
| Hsieh, RK | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Wang, WS | 1 |
| Chen, PM | 1 |
| Chou, CW | 1 |
| Liu, JM | 1 |
| Wu, MF | 1 |
| Li, AF | 1 |
| Tie, CM | 1 |
| Chi, KH | 1 |
| Sasahara, K | 1 |
| Uchida, Y | 1 |
| Kamei, M | 1 |
| Matsuda, K | 1 |
| Kawabata, H | 1 |
| Nishioka, M | 1 |
| Yokota, T | 1 |
| Fujii, T | 1 |
| Roppongi, T | 1 |
| Kanno, K | 1 |
| Ogata, T | 1 |
| Gerard, JP | 1 |
| Ayzac, L | 1 |
| Hun, D | 1 |
| Romestaing, P | 1 |
| Coquard, R | 1 |
| Ardiet, JM | 1 |
| Mornex, F | 1 |
| Falkson, G | 2 |
| Gelman, RS | 2 |
| Pandya, KJ | 1 |
| Osborne, CK | 1 |
| Tormey, D | 1 |
| Cummings, FJ | 2 |
| Sledge, GW | 1 |
| Abeloff, MD | 1 |
| Yamamoto, N | 1 |
| Katsumata, N | 1 |
| Omuro, Y | 1 |
| Ando, M | 1 |
| Kurihara, T | 1 |
| Higashi, Y | 1 |
| Suemasu, K | 1 |
| Tabei, T | 1 |
| Ishiguro, S | 1 |
| Iino, Y | 1 |
| Morishita, Y | 1 |
| Takeda, F | 1 |
| Pincemaille, B | 1 |
| Besançon, C | 1 |
| Balme, B | 1 |
| Devaux, Y | 1 |
| Thomas, L | 1 |
| Maekawa, Y | 1 |
| Furuya, Y | 1 |
| Toyokawa, A | 1 |
| Kinugasa, T | 1 |
| Fukano, S | 1 |
| Sekimoto, K | 1 |
| Kohno, N | 1 |
| Dhingra, K | 1 |
| Frye, D | 1 |
| Newman, RA | 1 |
| Walters, R | 1 |
| Theriault, R | 1 |
| Fraschini, G | 1 |
| Smith, T | 1 |
| Buzdar, A | 1 |
| Fujitake, S | 1 |
| Maeda, Y | 1 |
| Shimizu, M | 1 |
| Tohyama, M | 1 |
| Kataoka, S | 1 |
| Koizumi, M | 2 |
| Matsumoto, S | 1 |
| Yamashita, T | 1 |
| Ogata, E | 2 |
| Nakanishi, K | 1 |
| Ueno, Y | 1 |
| Nakamura, N | 1 |
| Yoshikawa, H | 1 |
| Takeuchi, T | 1 |
| Tanihata, H | 1 |
| Masuda, M | 1 |
| Terada, M | 1 |
| Satoh, M | 1 |
| Okamoto, E | 1 |
| Nakaguchi, K | 1 |
| Furukawa, J | 1 |
| Shingai, T | 1 |
| Azama, T | 1 |
| Yoshioka, S | 1 |
| Katsumoto, Y | 1 |
| Morimoto, T | 1 |
| Okajima, S | 1 |
| Sue, F | 1 |
| Fukushima, H | 1 |
| Hanaoka, T | 1 |
| Goya, T | 1 |
| Levine, RA | 1 |
| Fleischli, MA | 1 |
| Iwatani, Y | 1 |
| Ohno, M | 1 |
| Kamigaki, T | 1 |
| Nakamura, T | 1 |
| Suzuki, Y | 1 |
| Iwasaki, T | 1 |
| Sinmaru, H | 1 |
| Kuroda, Y | 1 |
| Nishimura, H | 1 |
| Takasuna, K | 1 |
| Kondo, R | 1 |
| Hayashi, K | 1 |
| Munakata, Y | 1 |
| Kasuga, Y | 1 |
| Zheng, X | 1 |
| Dai, A | 1 |
| Venturino, A | 1 |
| Comandini, D | 1 |
| Simoni, C | 1 |
| Merlini, L | 1 |
| Naso, C | 1 |
| Palumbo, R | 1 |
| Fusco, V | 1 |
| Porcile, G | 1 |
| Pronzato, P | 1 |
| Rosso, R | 2 |
| Repetto, L | 1 |
| Mitsuyama, S | 1 |
| Anan, K | 1 |
| Kokufu, I | 1 |
| Taniguchi, H | 1 |
| Fukuda, K | 1 |
| Yamamoto, M | 1 |
| Yano, T | 1 |
| Yamada, K | 1 |
| Kitano, H | 1 |
| Kaiga, T | 1 |
| Ueda, T | 1 |
| Fujii, M | 1 |
| Hirao, S | 1 |
| Baz, DV | 1 |
| Bofill, JS | 1 |
| Nogueira, JA | 1 |
| Kammori, M | 1 |
| Seto, Y | 1 |
| Haniuda, N | 1 |
| Kawahara, M | 1 |
| Takubo, K | 1 |
| Endo, H | 1 |
| Kaminishi, M | 1 |
| Franzke, A | 1 |
| Buer, J | 1 |
| Probst-Kepper, M | 1 |
| Lindig, C | 1 |
| Framzle, M | 1 |
| Schrader, AJ | 1 |
| Ganser, A | 1 |
| Atzpodien, J | 1 |
| Zeng, J | 1 |
| Hu, Y | 1 |
| Pei, F | 1 |
| Lei, S | 1 |
| Mao, Y | 1 |
| Wei, Y | 1 |
| Auerbach, M | 1 |
| Elias, EG | 1 |
| Orford, J | 1 |
| Nicholson, BP | 1 |
| Paul, DM | 1 |
| Hande, KR | 1 |
| Shyr, Y | 1 |
| Meshad, M | 1 |
| Cohen, A | 1 |
| Ortmann, E | 1 |
| Hohenberg, G | 1 |
| Elias, K | 1 |
| Weiss, RB | 1 |
| DeVita, VT | 3 |
| Dickerson, JW | 1 |
| Soloway, MS | 1 |
| Shippel, RM | 1 |
| Ikard, M | 1 |
| Smith, TL | 1 |
| Swenerton, KD | 1 |
| Gehan, EA | 1 |
| Bodey, GP | 1 |
| Freireich, EJ | 1 |
| Brufman, G | 1 |
| Schächner, E | 1 |
| Biran, S | 2 |
| Hill, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 1 |
| Wilson, WL | 1 |
| Davis, HL | 1 |
| Grage, T | 1 |
| Golomb, FM | 1 |
| Cruz, AB | 1 |
| Schmidt, JD | 1 |
| Gibbons, RP | 1 |
| Prout, GR | 1 |
| Scott, WW | 1 |
| Murphy, GP | 1 |
| Chen, SH | 1 |
| Nishimoto, T | 1 |
| Kikuike, A | 1 |
| Yonezawa, H | 1 |
| Yamamuro, T | 1 |
| Gallmeier, WM | 1 |
| Bruntsch, U | 1 |
| Schmidt, CG | 1 |
| Gillespie, PJ | 1 |
| Alexander, JL | 1 |
| Edelstyn, GA | 1 |
| Creech, RH | 1 |
| Catalano, RB | 1 |
| Mastrangelo, MJ | 1 |
| Engstrom, PF | 1 |
| De Lena, M | 2 |
| Brambilla, C | 2 |
| Morabito, A | 1 |
| Canellos, GP | 2 |
| Gold, GL | 2 |
| Chabner, BA | 2 |
| Schein, PS | 2 |
| Young, RC | 2 |
| Sasaki, T | 1 |
| Ibuka, T | 1 |
| Imai, K | 1 |
| Sakaki, N | 1 |
| Tabata, I | 1 |
| Ishiwata, J | 1 |
| Onozawa, Y | 1 |
| Zola, P | 1 |
| Bergamino, T | 1 |
| Katsaros, D | 1 |
| Ferrero, A | 1 |
| Ciancio, A | 1 |
| Bellora, G | 1 |
| Sismondi, P | 1 |
| Morere, JF | 1 |
| Boaziz, C | 1 |
| Haraf, DJ | 1 |
| Vokes, EE | 1 |
| Panje, WR | 1 |
| Weichselbaum, RR | 1 |
| Romero, JA | 1 |
| Alvarez-Vijande, R | 1 |
| Gil-Vernet, JM | 1 |
| Samsón, R | 1 |
| Fernández, I | 1 |
| Gutiérrez, R | 1 |
| Carretero, P | 1 |
| Korman, DB | 1 |
| Snimshchikov, VA | 1 |
| Dobroskok, LB | 1 |
| Maslova, IA | 1 |
| Mikaélian, SG | 1 |
| Pines, EV | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Bast, RC | 1 |
| Rosner, GL | 1 |
| Vandermark, R | 1 |
| Johnston, C | 1 |
| Eggleston, S | 1 |
| Tepperburg, M | 1 |
| Tunn, UW | 1 |
| Goldschmidt, AJ | 1 |
| Peter, K | 1 |
| Becker, M | 1 |
| Thomas, G | 1 |
| Dembo, A | 1 |
| DePetrillo, A | 1 |
| Pringle, J | 1 |
| Ackerman, I | 1 |
| Bryson, P | 1 |
| Balogh, J | 1 |
| Osborne, R | 1 |
| Rosen, B | 1 |
| Fyles, A | 1 |
| Benahmed, M | 1 |
| Carde, P | 1 |
| Laplanche, A | 1 |
| Renaux, J | 1 |
| Rouesse, J | 1 |
| Spielmann, M | 1 |
| Sancho-Garnier, H | 1 |
| Benasso, M | 1 |
| Ferro, A | 1 |
| Bacigalupo, A | 1 |
| Toma, S | 1 |
| Vitriolo, S | 1 |
| Merlano, M | 1 |
| Katsumi, T | 1 |
| Murayama, K | 1 |
| Inoue, K | 1 |
| Horikoshi, N | 1 |
| Mukaiyama, T | 1 |
| Ogawa, M | 1 |
| Kuraishi, Y | 1 |
| Ellis, GK | 1 |
| Green, S | 1 |
| Schulman, S | 1 |
| Tranum, BL | 1 |
| Goldberg, RS | 1 |
| Livingston, RB | 1 |
| Bruckner, HW | 1 |
| Crown, J | 1 |
| McKenna, A | 1 |
| Hart, R | 1 |
| Doroshow, JH | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Flanagan, B | 1 |
| Goldberg, D | 1 |
| Bertrand, M | 1 |
| Akman, S | 1 |
| Carr, B | 1 |
| Odujinrin, O | 1 |
| Litchfield, T | 1 |
| Sadamoto, Y | 1 |
| Haruma, K | 1 |
| Tokumo, K | 1 |
| Teshima, H | 1 |
| Murakami, S | 1 |
| Sumii, K | 1 |
| Kajiyama, G | 1 |
| Yamashita, Y | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Büyükünal, E | 1 |
| Derman, U | 1 |
| Serdengecti, S | 1 |
| Berkarda, B | 1 |
| Kato, Y | 1 |
| Tashima, M | 1 |
| Sawada, H | 1 |
| Yamagishi, M | 1 |
| Uchino, H | 1 |
| Carpenter, JT | 1 |
| Raney, M | 1 |
| Vogel, CL | 1 |
| Weiner, RS | 1 |
| Aisner, J | 1 |
| Weinberg, V | 1 |
| Perloff, M | 1 |
| Weiss, R | 1 |
| Perry, M | 1 |
| Korzun, A | 1 |
| Ginsberg, S | 1 |
| Holland, JF | 1 |
| Rieche, K | 1 |
| Dabag, S | 1 |
| Scharlau, L | 1 |
| Gritsaĭ, AA | 2 |
| Lichinitser, MR | 2 |
| Vyshinskaia, GV | 2 |
| Kondrat'eva, AP | 2 |
| Aplevich, NN | 1 |
| Gez, E | 1 |
| Pfeffer, MR | 1 |
| Catane, R | 1 |
| Isacson, R | 1 |
| Gregory, EJ | 1 |
| Cohen, SC | 1 |
| Oines, DW | 1 |
| Mims, CH | 1 |
| Tormey, DC | 1 |
| Carbone, PP | 1 |
| Falkson, HC | 1 |
| Luk'ianchenko, AB | 1 |
| Komatsu, K | 1 |
| Hiratsuka, H | 1 |
| Kamisasa, A | 1 |
| Inaba, Y | 1 |
| Linder, GT | 1 |
| Crook, JN | 1 |
| Cohn, I | 1 |
| Takagi, M | 1 |
| Ishikawa, G | 1 |
| Akarhoshi, Y | 1 |
| Nishimgto, T | 1 |
| Ammon, J | 1 |
| Hermann, HJ | 1 |
| Janssen, B | 1 |
| Schmidt, L | 1 |
| Günther, W | 1 |
| Sugarbaker, PH | 1 |
| Skarin, AT | 1 |
| Wilson, RE | 2 |
| Perlia, CP | 1 |
| Chauvin, HF | 1 |
| Nathanson, L | 1 |
| Hall, TC | 2 |
| Schilling, A | 1 |
| Miller, S | 1 |
| Fisher, B | 1 |
| Ravdin, RG | 1 |
| Ausman, RK | 1 |
| Slack, NH | 1 |
| Moore, GE | 1 |
| Noer, RJ | 1 |
| Gordan, GS | 1 |
| Wessler, S | 1 |
| Avioli, LV | 1 |
| Lahiri, SR | 1 |
| Boileau, G | 1 |
| Piro, AJ | 1 |
| Aliapoulios, MA | 1 |
| Moore, FD | 1 |
| Deemarsky, LY | 2 |
| Chernomordikova, MF | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.[NCT01640405] | Phase 3 | 350 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells[NCT01640444] | Phase 2 | 240 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Randomized, Phase II, Placebo-controlled Study of Ipatasertib (GDC-0068), an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT01896531] | Phase 2 | 153 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis[NCT01784393] | Phase 2 | 29 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable [NCT01248299] | Phase 2 | 105 participants (Actual) | Interventional | 2011-01-31 | Terminated | ||
| Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.[NCT02460419] | Phase 3 | 104 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2[NCT05301010] | Phase 3 | 128 participants (Actual) | Interventional | 2018-02-02 | Completed | ||
| Randomized, Single-blind, Multicenter, Parallel Group Clinical Trial to Assess Pharmacokinetic Parameters, Safety of NNG-TMAB (Trastuzumab) in Combination With Docetaxel on Recurrent or Metastatic Breast Cancer Patients With Positive HER2.[NCT05301530] | Phase 1 | 50 participants (Actual) | Interventional | 2019-05-27 | Completed | ||
| A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer[NCT01642771] | Phase 3 | 636 participants (Anticipated) | Interventional | 2012-06-30 | Active, not recruiting | ||
| Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial[NCT03503136] | Phase 3 | 632 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | ||
| MITOXANTRONE (N) VS. 5-FLUOROURACIL, EPIRUBICIN AND CYCLOPHOSPHAMIDE AS FIRST-LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC BREAST CANCER AND AN UNFAVORABLE PROGNOSIS[NCT00002544] | Phase 3 | 300 participants (Anticipated) | Interventional | 1993-05-31 | Completed | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome[NCT00673816] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2008-05-31 | Terminated (stopped due to Inability to recruit and adequate number of participants) | ||
| A Randomized Trial of High-Dose Chemotherapy and Autologous Stem Cell Therapy Versus Standard Therapy in Women With Metastatic Breast Cancer Who Have Responded to Anthracycline or Taxane-Based Induction Chemotherapy[NCT00003032] | Phase 3 | 224 participants (Actual) | Interventional | 1997-04-25 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Phase I/II of Capecitabine and Vinorelbine in Elderly Patients (At Least 65 Years) With Metastatic Breast Cancer With or Without Bone Involvement[NCT00003902] | Phase 1/Phase 2 | 110 participants (Anticipated) | Interventional | 1999-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. (NCT01896531)
Timeframe: Baseline until end of study (up to approximately 7.5 years)
| Intervention | Participants (Count of Participants) |
|---|---|
| Ipatasertib + mFOLFOX6 | 70 |
| Placebo + mFOLFOX6 | 80 |
Duration of objective tumor response in participants with measurable soft tissue disease at baseline was defined as the time from first observation of an objective tumor response until first observation of disease progression, as assessed by the investigator per modified RECIST Version 1.1. PD: At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumor | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 4.63 | 4.70 | 4.70 |
| Placebo + mFOLFOX6 | 5.85 | 5.98 | 6.80 |
Objective Response Rate was defined as the percentage of participants achieving either a complete response (CR) or a partial response (PR) based on the investigator assessment using RECIST v 1.1. CR: disappearance of all target lesions and all pathological lymph nodes below 10 mm. Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, up to end of study (up to approximately 7.5 years)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 52.1 | 50.0 | 52.2 |
| Placebo + mFOLFOX6 | 57.3 | 73.3 | 56.5 |
OS was defined as the time from the date of randomization to the date of death from any cause. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Baseline up to end of study (up to approximately 7.5 years)
| Intervention | months (Median) | ||
|---|---|---|---|
| Randomized | PTEN Loss Tumors | Akt Dx+ | |
| Ipatasertib + mFOLFOX6 | 11.96 | 14.82 | 11.66 |
| Placebo + mFOLFOX6 | 15.31 | 21.78 | 17.22 |
PFS was defined as the time from randomization to the first occurrence of disease progression (as determined using RECIST Version 1.1 and assessed by the investigator), or death from any cause on study. Progressive disease (PD): At least a 20% increase in the sum of diameters of target lesions, and the sum must also demonstrate an absolute increase of at least 5 mm or progression of non-target lesions. Death on study was defined as death from any cause within 30 days of the last dose of study treatment regimen. Kaplan-Meier estimates were used for evaluation. (NCT01896531)
Timeframe: Screening, at the end of Cycle 4 (cycle = 14 days) and every fourth cycle thereafter until disease progression or death, whichever occurred first, assessed up to approximately 1.75 years
| Intervention | months (Median) | |
|---|---|---|
| All Randomized Participants | Participants With PTEN Loss Tumors | |
| Ipatasertib + mFOLFOX6 | 6.57 | 7.10 |
| Placebo + mFOLFOX6 | 7.52 | 7.39 |
(NCT01896531)
Timeframe: Day 1 at 1 hour and 4 hours post-dose; Day 5, pre-dose and 2 hours post-dose
| Intervention | ng/mL (Mean) | |||
|---|---|---|---|---|
| Day 1: 1 hour post-dose | Day 1: 4 hours post-dose | Day 5: pre-dose | Day 5: 2 hours post-dose | |
| Ipatasertib + mFOLFOX6 | 506 | 389 | 90.7 | 557 |
Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 6 |
The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Genistein | 8 |
Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 36.5 |
Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Percent change (Median) |
|---|---|
| Genistein | -43.0 |
Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months
| Intervention | months (Median) |
|---|---|
| Genistein | 11.5 |
"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 6 | 3 | 2 | 2 |
Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Genistein | 250 | 119 | 24 | 0 |
"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| Genistein | 69 | 38 |
"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| PR | SD | PD | Not evaluable | |
| Genistein | 8 | 1 | 2 | 2 |
Visual acuity was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol. Acuity is measured as letters read on an ETDRS eye chart and the letters read equate to Snellen measurements. For example, if a participant reads between 84 and 88 letters, the equivalent Snellen measurement is 20/20. (NCT00673816)
Timeframe: Baseline and 36 Weeks
| Intervention | ETDRS Letters (Number) |
|---|---|
| Left Eye | 1 |
| Right Eye | -5 |
Retinal thickness was assessed by spectral-domain optical coherence tomography (Cirrus HD-OCT; Carl Zeiss Meditec, Dublin, CA), a non-invasive imaging technique that uses long-wavelength light to capture micrometer-resolution cross-sectional images from biological tissue. (NCT00673816)
Timeframe: Baseline and 36 Weeks
| Intervention | µm (Number) |
|---|---|
| Left Eye | 116 |
| Right Eye | 1 |
14 reviews available for fluorouracil and Bone Neoplasms
| Article | Year |
|---|---|
Gastrointestinal malignancy in cystic fibrosis.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2020 |
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Cap | 2011 |
[Chemotherapy for metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; An | 2006 |
[Optimal chemotherapy for advanced and recurrent breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2007 |
Preclinical investigations with epothilones in breast cancer models.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Cl | 2008 |
Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Neoplasms; Cisplatin; Clinical Trials as Topic; | 1993 |
Recurrent breast cancer: presentation, diagnosis, and treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast | 1993 |
[Systemic therapy, pain relief and quality of life of breast cancer patients with bone metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials as | 1995 |
Eyelid metastasis from breast cancer showing marked response to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular | 1995 |
[Medroxyprogesterone acetate for treatment of advanced breast cancers].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2000 |
Irinotecan-induced dysarthria.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto | 2001 |
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Evaluation Stud | 1979 |
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; | 1989 |
Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
Topics: Acid Phosphatase; Adenocarcinoma; Aniline Compounds; Bone Neoplasms; Cyclophosphamide; Evaluation St | 1973 |
81 trials available for fluorouracil and Bone Neoplasms
| Article | Year |
|---|---|
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu | 2020 |
A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2019 |
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla | 2019 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorou | 2013 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone | 2013 |
Phase II study of concurrent capecitabine and external beam radiotherapy for pain control of bone metastases of breast cancer origin.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemoradiotherapy; D | 2013 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2015 |
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Mass Index; Bone Neoplasms; C | 2016 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal | 2008 |
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2008 |
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot | 2009 |
(188)Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Eti | 2009 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
Modular therapy approach in metastatic castration-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Capecitabine; Deoxycytidine; Dexamet | 2010 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin | 2011 |
Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant | 2010 |
[Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capec | 2011 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2013 |
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast | 2002 |
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capec | 2003 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bo | 2004 |
Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2005 |
Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Epirubici | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle | 2005 |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; | 2006 |
A pilot phase II study of capecitabine in advanced or recurrent breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms | 2006 |
A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2006 |
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec | 2007 |
[Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2007 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2008 |
Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combi | 2008 |
Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Br | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; | 2007 |
Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neop | 2007 |
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2008 |
[Calcitonin in bone-metastasizing breast carcinoma. Results of a pilot study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Calci | 1984 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
Topics: Acid Phosphatase; Aged; Bone Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Fluo | 1984 |
A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone (CMFVP) in patients with advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1983 |
Combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in advanced breast carcinoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1980 |
Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cyclop | 1980 |
Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
Topics: Aged; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Hu | 1981 |
Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admini | 1994 |
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1995 |
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 1995 |
Effect of systemic adjuvant treatment on first sites of breast cancer relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adju | 1994 |
Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone | 1994 |
[Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1994 |
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1993 |
[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; | 1993 |
Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy P | 1993 |
Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth | 1996 |
Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosph | 1998 |
Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1995 |
Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal | 2000 |
Paclitaxel, 5-fluorouracil, and leucovorin (TFL) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2000 |
A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; | 1977 |
Chemotherapy of advanced prostatic cancer. Evaluation of response parameters.
Topics: Aged; Body Weight; Bone Marrow Examination; Bone Neoplasms; Cyclophosphamide; Drug Evaluation; Fluor | 1976 |
[Chemotherapy of metastasizing breast cancers. Indications and results].
Topics: Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fema | 1975 |
Response and survival in advanced breast cancer after two non-cross-resistant combinations.
Topics: Antineoplastic Agents; Blood Cell Count; Blood Platelets; Bone Neoplasms; Breast Neoplasms; Cyclopho | 1976 |
Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Doxor | 1992 |
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 1991 |
[Comparative evaluation of 2 schedules of administration of anti- neoplastic drugs by the CMF protocol in disseminated breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; Drug Ad | 1991 |
4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Bon | 1991 |
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1991 |
Late effects of adjuvant oophorectomy and chemotherapy upon premenopausal breast cancer patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 1990 |
Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; C | 1989 |
Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1988 |
Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cl | 1988 |
A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clini | 1987 |
Ineffectiveness of levamisole in prolonging remission or survival of women treated with cyclophosphamide, doxorubicin, and 5-fluorouracil for good-risk metastatic breast carcinoma: a Southeastern Cancer Study Group Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials as | 1986 |
Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Topics: Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bone Neoplasms; Breast Neoplasms; Cispl | 1987 |
The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1985 |
Concurrent combination chemotherapy of human solid tumors: experience with a three-drug regimen and review of the literature.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Neoplasms; Carcinoma; Child; Child, Preschool; Clinical T | 1969 |
Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
Topics: Adult; Aged; Axilla; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouraci | 1968 |
228 other studies available for fluorouracil and Bone Neoplasms
| Article | Year |
|---|---|
Selective bone targeting 5-fluorouracil prodrugs: synthesis and preliminary biological evaluation.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Chromatography, Hig | 2011 |
From tryptophan to novel mitochondria-disruptive agent, synthesis and biological evaluation of 1,2,3,6-tetrasubstituted carbazoles.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carbazoles; Cell Line, Tumor; Cell Proliferation; | 2022 |
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.
Topics: Bevacizumab; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hu | 2022 |
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 | 2020 |
Therapeutic Effect of Chemotherapy Cycle in Nasopharyngeal Carcinoma (NPC) Patients Who Developed Bone-Only Metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Cisplatin; Doceta | 2020 |
Multimodal Therapy of Squamous Cell Carcinoma of the Anus With Distant Metastasis: A Single-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone | 2017 |
Post-Transcriptional Control of Angiotensin II Type 1 Receptor Regulates Osteosarcoma Cell Death.
Topics: Aged; Animals; Apoptosis; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Disease Pr | 2018 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Ce | 2013 |
[Combination therapy herceptin+xeloda].
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2002 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neop | 2013 |
Combination chemotherapy for metastatic extramammary Paget disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Neopla | 2014 |
Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Capecitab | 2014 |
Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Daunorubicin; Etoposide; Fluorouracil; Gluc | 2014 |
XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2014 |
[A case of lacrimal duct obstruction caused by capecitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine | 2015 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cam | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
[Long-term survival in a patient receiving multidisciplinary therapy for hepatocellular carcinoma with left iliac bone metastasis].
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocell | 2014 |
Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2015 |
In vitro and in vivo toxicity of 5-FdU-alendronate, a novel cytotoxic bone-seeking duplex drug against bone metastasis.
Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Bone Density Conservation Agents; Bone Neopla | 2015 |
Concomitant chemoradiotherapy for advanced squamous cell carcinoma of the temporal bone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
Prostate Cancer Heterogeneous High-Metastatic Multi-Organ-Colonizing Chemo-Resistant Variants Selected by Serial Metastatic Passage in Nude Mice Are Highly Enriched for Multinucleate Giant Cells.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubi | 2015 |
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
Second-Line Modified FOLFOX6 Regimen in The Patients with Metastatic Esophagus Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 2015 |
Anticancer drugs with chemotherapeutic interactions with thymoquinone in osteosarcoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Bone Neoplasms; Cell Proliferation; Cell Survival; | 2016 |
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bili | 2017 |
Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Topics: Alendronate; Animals; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Caspases; Cell | 2017 |
Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Marrow; Bone | 2017 |
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Co | 2017 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; F | 2008 |
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2009 |
Gastric phenotype signet-ring cell carcinoma of the stomach with multiple bone metastases effectively treated with sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Female; | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci | 2009 |
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 2009 |
Dose-finding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 2009 |
[Clinical analysis of 22 cases of esophageal adenosquamous carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Adenosquamou | 2009 |
Subdural collections arising from calvarial metastases following discontinuation of anti-angiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Cell Cycle; Cell Proliferation; Colonic Neoplasms; | 2009 |
Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2010 |
Memoirs of differential radiation doses: Gemcitabine induced radiation recall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin | 2010 |
[Analysis of responses and prognostic factors in different chemotherapy regimens for metastatic nasopharyngeal carcinoma: a report of 171 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2009 |
[A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2010 |
[An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deox | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato | 2011 |
The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.
Topics: Antineoplastic Agents; Bone Neoplasms; Bromodeoxyuridine; Camptothecin; Cell Growth Processes; Cell | 2010 |
[Long-term control of sacral metastasis from rectal cancer with S-1 + radiation treatment (RT) and mFOLFOX6 combination therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Dru | 2010 |
Sternal metastasis of breast cancer: ex vivo hypothermia and reimplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Breast Neoplasms; Ca | 2011 |
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo | 2011 |
Cisplatin as an active treatment in zoledronate-refractory hypercalcemia.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma | 2011 |
Bevacizumab in the treatment of metastatic breast cancer: three case reports.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[Successful withdrawal from disseminated intravascular coagulation caused by disseminated carcinomatosis of bone marrow originated from gastric cancer treated by sequential therapy consisting of MTX and 5-FU and palliative radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intravascular Coagulati | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast | 2011 |
Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma | 2011 |
[Eighty-five-year-old patient with recurrent rectal cancer effectively treated with CapeOX chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Deo | 2011 |
A patient with a metastatic gastroenteropancreatic endocrine carcinoma causing hyperinsulinaemic hypoglycaemia and the carcinoid syndrome.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Fl | 2011 |
Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbo | 2012 |
A primary signet ring cell carcinoma of the prostate with bone metastasis with impressive response to FOLFOX and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Cell Line; Cytokines; DNA Damage; DNA, Neoplasm; D | 2012 |
Relationship between antimetabolite toxicity and pharmacogenetics in Turkish cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alleles; Antimetabolites, Antineop | 2012 |
Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Topics: Adenocarcinoma; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, | 2012 |
Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conserv | 2012 |
Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; | 2013 |
[A case of advanced rectal cancer with lung and bone metastasis that was successfully treated with mFOLFOX6+bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone | 2012 |
Radiation recall dermatitis may represent the Koebner phenomenon.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine | 2002 |
[A case of recurrent breast cancer with carcinomatous pleurisy successfully treated with combined chemoendocrine-therapy of CTF (CPA, THP and 5-FU) and anastrozole following instillation therapy 12 years after radical mastectomy].
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carci | 2002 |
[A case of irinotecan-resistant colon cancer responding to chronotherapy with oxaliplatin, 5-FU, l-LV].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Chronotherapy; C | 2003 |
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bo | 2003 |
INDIVIDUALIZED CHEMOTHERAPY BY IN VITRO DRUG SELECTION.
Topics: Antineoplastic Agents; Bone Neoplasms; Dactinomycin; Female; Floxuridine; Fluorouracil; Genital Neop | 1964 |
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, | 1964 |
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci | 1964 |
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Doxorubici | 2003 |
Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Th | 2003 |
[Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; D | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; | 2003 |
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothera | 2003 |
[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2004 |
[A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated I | 2004 |
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Coloni | 2004 |
Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery.
Topics: Animals; Bone Neoplasms; Bystander Effect; Carcinoma, Lewis Lung; Cell Hypoxia; Cytosine Deaminase; | 2004 |
Toxic encephalopathy induced by capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Epil | 2004 |
[Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2004 |
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E | 2004 |
Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2004 |
Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Diphosphonates; Female; Fluorouracil; Huma | 2004 |
188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases.
Topics: Animals; Bone Neoplasms; Diphosphonates; Female; Fluorouracil; Isotope Labeling; Mice; Mice, Inbred | 2005 |
[A case of advanced gastric cancer with bone metastasis and severe DIC responding to hypertensive subselective chemotherapy with pharmacokinetic modulating chemotherapy].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ri | 2005 |
Preferential inhibition of bone metastases by 5'-deoxy-5-fluorouridine and capecitabine in the 4T1/luc mouse breast cancer model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capec | 2005 |
Osteoclasts direct bystander killing of cancer cells in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Bone Neoplasms; Breast Neoplasms; Cell | 2006 |
Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Re | 2006 |
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Treatment outcomes of patients with AJCC stage IVC nasopharyngeal carcinoma: benefits of primary radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisp | 2006 |
Acute coronary syndrome induced by oral capecitabine.
Topics: Acute Disease; Administration, Oral; Adult; Angina, Unstable; Antimetabolites, Antineoplastic; Bone | 2006 |
Acute coronary syndrome secondary to fluorouracil infusion.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2006 |
[Metastatic nasopharyngeal carcinoma: clinical study and therapeutic results of 95 cases].
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2006 |
Corticosteroids induce chemotherapy resistance in the majority of tumour cells from bone, brain, breast, cervix, melanoma and neuroblastoma.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Biological Assay; Bone Neoplasms; Brain Neoplasms; Breas | 2006 |
[Therapeutic efficacy of capecitabine on advanced and recurrent breast cancer with special reference to time to progression].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; C | 2006 |
[Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2006 |
A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2006 |
[Breast carcinoma and bone chondrosarcoma: a new syndrome?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Breas | 2006 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone | 2006 |
[A case of progressive gastric carcinoma accompanied by disseminated carcinomatosis of bone marrow due to bone metastasis with DIC recovery by joint administration of 5-FU and paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bo | 2006 |
[A patient with advanced breast cancer refractory to chemotherapy accompanied by carcinomatous pleurisy and multiple bone metastasis that responded to combination therapy with high-dose toremifene and docetaxel].
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 2007 |
[Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2007 |
Identification of uPAR-positive chemoresistant cells in small cell lung cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2007 |
Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; C | 2007 |
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxyc | 2007 |
Male breast cancer with mandibular metastasis. A case report.
Topics: Aged; Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplast | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 2007 |
[Diagnosis and prognosis study of breast carcinoma with micropapillary component].
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2007 |
Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cispl | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi | 2007 |
[A case of advanced breast cancer leading to DIC after chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2007 |
[Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2009 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma--a pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carmustine; Child; Fluor | 1984 |
Intra-arterial chemotherapy using an implantable infusion pump and liver irradiation for the treatment of hepatic metastases.
Topics: Adult; Aged; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Drug Admin | 1982 |
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; | 1984 |
[Bone metastasis of breast cancer. Apropos of a series of 50 cases].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1982 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev | 1983 |
[Adriablastin (doxorubicin) in the combined chemotherapy of patients with disseminated forms of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
Orchiectomy and chemotherapy with estramustine, cis-platinum, cyclophosphamide, and 5-fluorouracil in newly diagnosed prostate cancer with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Cisplatin; Combined Moda | 1984 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1984 |
[Use of adriamycin in the treatment of metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Castr | 1984 |
[Sick sinus syndrome probably caused by cardiac metastases].
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Electrocardiography; Female; Fluorouracil; Heart | 1983 |
Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1983 |
High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Colonic Neoplasms; Diphosphon | 1983 |
Early combined hormonal and chemotherapy for metastatic prostatic carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma; Castration; Cyclophosphamide; Diethylstilbestrol; Fluorouracil; Hum | 1983 |
Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1981 |
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N | 1982 |
Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Dox | 1982 |
[Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1982 |
Radiographic evaluation of therapeutic response in bony metastases of breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat | 1981 |
The predictive value of serial bone scans in assessing response to chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cyclophosphami | 1980 |
The non-hormone chemotherapy of prostatic cancer.
Topics: Bone Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Humans; Lung Neoplasms; M | 1980 |
Pericardiac metastasis from advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Fluorouracil; Heart Neoplasms; Human | 1995 |
Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy.
Topics: Aged; Bone Marrow Diseases; Bone Neoplasms; Carcinoma, Signet Ring Cell; Facial Neoplasms; Fluoroura | 1995 |
[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cy | 1994 |
High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Brain Neoplasms; | 1994 |
[A case of nonresectable gastric cancer treated by sequential methotrexate and 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Admi | 1994 |
[Advanced breast cancer with onset of multi-organ metastases successfully treated with combined loco-regional therapies: a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Ch | 1993 |
Hormonal therapy in the treatment of mandibular metastasis of breast carcinoma. Report of a case.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, | 1993 |
[A case of giant advanced breast cancer responding remarkably to CEFT therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1993 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcin | 1995 |
[FAM as a palliative chemotherapy for gastric cancer with bone metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intrava | 1996 |
Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dr | 1996 |
Treatment of advanced breast cancer: How much chemotherapy is enough?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 1996 |
[A case of advanced gastric cancer responding to chemotherapy and radiotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cispl | 1996 |
Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 1995 |
Low-dose prednisone and increased risk of development of bone metastases.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bon | 1996 |
[A case of breast cancer metastasis to the skin and bone 13 years after, and to the brain 17 years after mastectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; C | 1997 |
[A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Co | 1997 |
Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasm | 1997 |
Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 1997 |
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, | 1998 |
[A case report of advanced breast cancer with remarkable response to chemoendocrine therapy (CTF + MPA)].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 1998 |
Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1998 |
Multidrug-resistant recurrent breast cancer which responded to medroxyprogesterone acetate showing a remarkable improvement in the quality of life: report of a case and the role of team medical care.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 1998 |
[Membranous lipodystrophy caused by chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas | 1998 |
[A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Diphosp | 1998 |
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, D | 1998 |
Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Topics: Adult; Alkaline Phosphatase; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1999 |
[Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Colonic Ne | 1999 |
[A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1999 |
[Successful endocrine chemotherapy in patients with multiple bone metastases of breast cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1999 |
Inactivation of p53 and retinoblastoma family pathways in canine osteosarcoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Northern; Blotting, Western; Bone Neoplasms; DNA | 2000 |
[A case of gastric cancer with liver metastasis responding to low-dose CDDP/5-FU combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Admi | 2000 |
[A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2000 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 1998 |
[Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2000 |
[A case of advanced breast cancer that responded remarkably to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2000 |
Transient splenic accumulation of Tc-99m HMDP caused by megaloblastic anemia.
Topics: Anemia, Megaloblastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 2000 |
[Advanced breast cancer with multiple bone metastases successfully treated with combined chemoendocrine-therapy of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) and 5'-DFUR (5'-deoxy-5-fluorouridine) + MPA (medroxyprogesterone acetate)--a case report
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre | 2001 |
A case of bone metastasis from gastric carcinoma after a nine-year disease-free interval.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined | 2001 |
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Renal C | 2001 |
[Flow cytometry for testing chemosensitivity of malignant bone tumors].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Neop | 1999 |
Experience with methotrexate, 5-fluorouracil, and leucovorin (MFL): a first line effective, minimally toxic regimen for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brai | 2002 |
Treatment side effects. Case 1. Radiation recall phenomenon after administration of capecitabine.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuv | 2002 |
Letter: Osteoblastic repair of osteolytic tumor metastases following treatment.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cyclophospham | 1975 |
Nutrition and breast cancer.
Topics: Animals; Ascorbic Acid; Bone Neoplasms; Breast Neoplasms; Calcium; Dietary Fats; Feeding Behavior; F | 1979 |
Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Drug The | 1979 |
Complete remissions in metastatic breast cancer treated with combination drug therapy.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Castration; Cycloph | 1979 |
Response to chemotherapy of breast carcinoma bone metastases: assessment by bone scan.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluoro | 1979 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
The role of nonspecific immunotherapy in the treatment of breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1976 |
The results of surgical treatment combined with intra-arterial infusion of anti-cancer agents in osteosarcoma.
Topics: Adolescent; Adult; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Child; Extremities; Fem | 1976 |
Changes in 87mSr concentractions in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; | 1975 |
Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy | 1975 |
Combination chemotherapy for advanced breast cancer: response and effect on survival.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Li | 1976 |
[Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 1992 |
[Rapid complete regression of liver, brain and bone metastases from previously treated breast cancer, with combination of platin, fluorouracil and lomustine].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopl | 1992 |
Alpha-interferon and oral fluorouracil in the treatment of unremovable and/or metastatic renal cancer.
Topics: Adult; Aged; Bone Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Interferon-alp | 1991 |
Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Moda | 1990 |
Concurrent radiation and chemotherapy in vulvar carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone | 1989 |
[Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial].
Topics: Ambulatory Care; Antineoplastic Agents; Bleomycin; Bone Neoplasms; Cisplatin; Disposable Equipment; | 1985 |
Analysis of 16 patients with metastatic squamous cell carcinoma of the head and neck: implications for treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cel | 1989 |
[A case of non-functioning adrenal cortical carcinoma with pulmonary and bony metastases].
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Agents; Bone Neoplasms; Combined Modality Th | 1989 |
[Advanced gastric cancer with DIC and multiple bone metastasis treated with surgical resection and chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Co | 1987 |
[A cancer of unknown primary site with diffuse metastasis to the bone marrow treated effectively with FAM combination chemotherapy].
Topics: Anemia, Myelophthisic; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; | 1988 |
[Combination of aminoglutethimide and polychemotherapy for the treatment of predominant bone metastasis in breast cancer].
Topics: Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; | 1986 |
[4-component chemotherapy and radiation therapy of breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality | 1986 |
Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Breast Neo | 1986 |
Megestrol acetate therapy for advanced breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; | 1985 |
[Criteria for evaluating the efficacy of treatment of breast cancer metastases to the bones].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1986 |
Widespread extracranial metastases of glioblastoma multiforme. Report of case and clinicopathological review of cases in literature.
Topics: Adolescent; Autopsy; Biopsy; Bone Neoplasms; Brain Neoplasms; Carotid Arteries; Cauda Equina; Cerebr | 1972 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
[Pathologic study of the therapeutic effects in the osteosarcoma treated with continuous intra-arterial infusion (author's transl)].
Topics: Adolescent; Bone and Bones; Bone Neoplasms; Child; Female; Fluorouracil; Humans; Injections, Intra-A | 1974 |
[Principles, technic and clinical performance of synchronized radiotherapy].
Topics: Adenocarcinoma; Adult; Aged; Androstanols; Bone Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, S | 1972 |
Thrombocytopenia from metastatic carcinoma of the breast. Effective managements of patients with this complication.
Topics: Adrenalectomy; Aged; Blood Cell Count; Blood Platelets; Bone Marrow; Bone Neoplasms; Breast Neoplasm | 1973 |
The problems of drug treatment of breast cancer.
Topics: Age Factors; Alkylating Agents; Androgens; Bone Neoplasms; Breast Neoplasms; Corticosterone; Drug Co | 1973 |
[Trial of combined intermittent chemotherapy in prostatic cancers. Estrogen resistant metastases].
Topics: Antibiotics, Antineoplastic; Bone Neoplasms; Drug Therapy, Combination; Estrogens; Fluorouracil; Fol | 1973 |
Cyclical combination chemotherapy for advanced breast carcinoma.
Topics: Adrenalectomy; Adult; Alopecia; Bone Marrow; Bone Neoplasms; Breast Neoplasms; Castration; Cyclophos | 1974 |
Calusterone in the therapy for advanced breast cancer.
Topics: Adenocarcinoma; Axilla; Bone Neoplasms; Breast Neoplasms; Castration; Drug Synergism; Female; Fluoro | 1972 |
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth.
Topics: Administration, Oral; Aged; Bone Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver C | 1971 |
Treatment of metastatic breast cancer with a combination of adrenalectomy and 5-fluorouracil. Progress report.
Topics: Adrenalectomy; Aged; Bone Neoplasms; Breast Neoplasms; Female; Fluorouracil; Follow-Up Studies; Huma | 1971 |
Combination chemotherapy in the management of breast cancer metastases.
Topics: Adult; Aged; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Synergism; Fe | 1970 |
Clinical and roentgenologic picture of the alterations obtained in the treatment of breast cancer osseous metastases.
Topics: Adrenal Cortex Hormones; Androgens; Azirines; Benzoates; Bone Neoplasms; Breast Neoplasms; Cyclophos | 1971 |